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Abstract 
Regulation of Type-2 Airway Inflammation in Cystic Fibrosis and Asthma 
 
Mason L. Donnell, PhD 
 
University of Pittsburgh, 2020 
 
 
Asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) patients 
can all experience type-2 airway inflammation. The aim of this research was to understand how 
type-2 airway inflammation is regulated in models of CF and asthma by the receptor for advanced 
glycation endproducts (RAGE). Previous studies indicate RAGE is crucial for induction of type-2 
airway inflammation. Intriguingly, RAGE and type-2 proinflammatory cytokines are elevated in 
CF patient sputum and during infection with Pseudomonas aeruginosa. This led to the hypothesis 
that RAGE regulates IL-13 induced mucus production seen in CF patients.  
Using a RAGE antagonist, this study shows RAGE regulates mucin gene MUC5AC 
expression, the expression of transcription factors regulating mucous metaplasia (CLCA1, SPDEF 
and FOXA3) and exotoxin-2 production in Non-CF and CF human bronchial epithelial cells 
(HBECs). By transfecting Non-CF and CF HBECs with dicer substrate siRNA (dsiRNA) to 
deplete RAGE expression, this study shows RAGE regulates these phenomena through activation 
of STAT6 upstream of mucous gene expression. CF HBECs were hyperresponsive to IL-13 
treatment with elevated MUC5AC, CLCA1 and FOXA3 expression, which may be driven by 
sustained activation of STAT6. To test the role of RAGE in vivo, exotoxin derived from P. 
aeruginosa was used to model type-2 airway inflammation in WT and RAGE knock-out mice 
(RAGE-/-). WT animals treated with exotoxin were found to develop mucus production, though 
this was absent in RAGE-/- animals. 
In a second study, RAGE regulation of IL-33 initiation of type-2 allergic airway 
inflammation (AAI) was investigated. Prior work shows WT mice exposed to allergens upregulate 
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IL-33 in the lung, while RAGE-/- mice do not significantly upregulate the cytokine alarmin. To 
further understand how RAGE regulates IL-33 production, this study hypothesized RAGE 
expressing type-1 alveolar epithelial cells (ATIs) release IL-33 in response to allergens. After 
stimulation with Alternaria alternata (AA), RAGE expressing murine ATIs did not release IL-33. 
Human alveolar organoids were also tested but were unable to release IL-33 after stimulation with 
AA. Collectively, these studies show RAGE plays a role in IL-13 induced mucus production in CF 
HBECs and that ATIs are not solely responsible for IL-33 release.   
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1.0 Pathology of Cystic Fibrosis & Asthma 
This study will address two major hypotheses of how RAGE regulates type-2 airway 
inflammation in cystic fibrosis and asthma. Prior studies have indicated RAGE regulates IL-13 
induced mucus production in mice and human airway epithelial cells. CF patients have increased 
levels of type-2 inflammation, which led to the hypothesis that RAGE regulates IL-13 induced 
mucus production in CF human airway epithelial cells (Fig. 1, H1). The second hypothesis 
addresses a previous finding that RAGE-/- mice treated with allergens have depleted levels of IL-
33, which activates type-2 innate lymphoid cells to produce IL-13 in the lung. Yet, it is still not 
understood which lung epithelial cells release IL-33 in response to allergens (Fig. 1, H2). This led 
to the hypothesis that RAGE expressing type-1 alveolar epithelial cells regulate IL-33 release 
during allergen stimulation. In order to address these hypotheses, is important to understand the 
pathology of CF and asthma and how type-2 inflammation plays a role in both diseases.  
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Figure 1: Major hypotheses and type-2 airway inflammation 
Inflammatory Stimulus: Exposure to allergens, viruses, or bacteria induce release of IL-33 from airway cells. RAGE-
/- animals exposed to allergens do not upregulate IL-33 like their WT counterparts. Immune Activation: IL-33 then 
bind to type-2 innate lymphoid cells (ILC2s, purple) activating their expansion and production of type-2 
proinflammatory cytokines IL-13 and IL-5 (red). Type-2 Airway Inflammation: IL-13 and IL-5 then induce mucus 
production, mucous hyperplasia (goblet cell proliferation), mucous metaplasia (differentiation to goblet cell) and 
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eotaxin-2 release to recruit eosinophils to the lung. H1=Hypothesis 1 addressing RAGE regulation of IL-13 effects on 
Non-CF and CF bronchial epithelium. H2=Hypothesis 2 addressing which lung epithelial cell is responsible for IL-33 
release in response to allergens (A). Lung epithelial cells recognize the presence of an allergen through pattern 
recognition receptor (PRR) signaling induced by allergen antigens. This then induces the epithelium to release 
cytokines alarmins, IL-33, IL-25 thymic stromal lymphopoietin (TSLP). These alarmins can then activate dendritic 
cells (DC) for antigen presentation. Antigen presenting cells, such as dendritic cells and alveolar macrophages (Mac) 
play a key role in type-2 airway inflammation. These immune cells express major histocompatibility complex II 
(MHC-II) that binds to the foreign antigen and presents it to the T-cell receptor (TCR) expressed on CD4+ T-cells 
activating their expansion to T-helper 2 (Th2) cells, which can further differentiate to Resident Memory T-cells (TRM). 
Activated Th2 cells produce type-2 cytokines, where IL-4 activates B-cells to produce polyclonal IgE and IL-5 
activates eosinophils (Eos) to release major basic protein (MBP). Polyclonal IgE then binds with high affinity to IgE 
receptors (IgER or FCεRII) expressed on mast cells (Mas) and basophils (Bas), sensitizing them to the allergen. Upon 
re-exposure of the allergic antigen, IgE crosslinks with the antigen and activates mast cells and basophils to 
degranulate and release histamines, which induces an immediate type-2 hypersensitivity reaction within minutes (B).  
1.1 Cystic Fibrosis 
1.1.1 CFTR function, structure and mutations 
CF is an autosomal recessive genetic disorder caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR). CFTR is located on chromosome 7 in humans and 
is expressed in multiple epithelial tissues, including the lung, pancreas, skin (sweat glands), brain 
and gastrointestinal tract [1,2]. It is a part of the ATP-binding cassette family of transporters 
facilitating the transport of chloride and bicarbonate ions into or out of the cell by utilizing ATP 
hydrolysis [3]. The transporter is comprised of seven domains: the N- and C-terminus, two 
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membrane spanning domains with six transmembrane helices each (MSD1 & 2), two nucleotide 
binding domains (NBD1 & 2) and a regulatory domain (RD) [4]. Activation of CFTR conductance 
is induced by cyclic-AMP (cAMP) activation of protein-kinase A (PKA) [5]. PKA then 
phosphorylates multiple residues on CFTR’s R-domain, leading to a conformational change that 
engages the NBD domains for ATP hydrolysis [4,6]. Mutations in CFTR are classified into six or 
seven subsets based on the effect of CFTR conductance, stability or expression.   
Traditionally, class I mutations of CFTR have been defined by no CFTR protein due to 
nonsense, frameshift or canonical splice site mutations (e.g. Gly542X, Arg553X). Class I has now 
been split into two classes (Class IA and Class IB) based on the specific mutation effect, though 
both still result in no CFTR protein [7]. Class IA is defined by mutations resulting in no mRNA 
(e.g. 1717-1G-A), whereas Class 1B (e.g. Gly542X) is defined by no protein.  Class II mutations 
result in misfolded CFTR that is degraded by proteases during trafficking from the endoplasmic 
reticulum to the golgi apparatus. This class is based on missense or amino acid deletion mutations 
(e.g. Phe508del, Asn1303Lys) [8]. Class III mutations result in CFTR production and successful 
trafficking to the membrane, though the transport’s gating function is impaired due to missense or 
aminoacid substitution mutations (e.g. Gly551Asp, Ser549Asn) [4]. Class IV missense and amino 
acid substitution mutations result in reduced chloride conductance through CFTR (e.g. Arg117His, 
Ala455Glu). Class V mutations occur due to splicing defects or missense mutations that result in 
decreased full length CFTR mRNA formation and therefore lack of functional CFTR (e.g. 
3849+10kbC-T, 2789+5G-A). Lastly, class VI mutations result in production of mRNA and 
protein, but decrease CFTR’s membrane stability (e.g. Gln412X) [2,8]. Rescued CFTR in patients 
who are on novel CFTR correctors may still retain plasma membrane instability even though the 
trafficking defect has been corrected ((r-rescued) Phe508del) [9]. 
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1.1.2 Pathophysiology of CF 
Over 85,000 individuals suffer from CF across the world with an expected life expectancy 
of around 50 years old [10]. CF pathophysiology is centered around aberrant or missing anion 
secretion or absorption through CFTR. Since CFTR is expressed in multiple tissues, its mutations 
affects multiple organs, including the skin, pancreas, intestines, brain and the lungs [8,11]. Humans 
have been documented to display signs of pancreatic inefficiency and salty skin since the 1600’s, 
which are both characteristic of CF pathophysiology [12]. Increased levels of sodium chloride 
build up on the skin of CF patients due to a net reduction in Cl- ion absorption through CFTR, 
which also reduces Na+ ion absorption. Pancreatic insufficiency is caused by lack of CFTR 
secretion of HCO3- from pancreatic ductal cells. This causes pancreatic juices to increase in acidity 
and dehydrate, which leads to decreased enzyme secretion via exocytosis and primes the gland for 
pancreatitis and fibrosis [13]. Fibrosis can then lead to destruction of beta cells in the pancreatic 
islets, which in turn decreases insulin resistance and insulin secretions [14]. This disruption in 
glucose regulation leads to 30-50% of CF patients developing CF related diabetes (CFRD), where 
patients with class I, II or II mutations are at higher risk [15–17]. CFTR mutations also affect the 
gastrointestinal track, where lack of CFTR Cl- secretions leads to increased acidity, dehydration, 
meconium ileus at birth, an altered microbiome and acid reflux disease [1,18]. 
CFTR is also expressed in the central and peripheral nervous systems. In pigs CFTR is 
expressed in neurons and glial cells, however in humans CFTR has only been identified in neuronal 
cells [19,20]. Since chloride ions play an excitatory role (depolarization) in peripheral neurons and 
an inhibitory role (hyperpolarization) in central neurons, it is plausible lack of CFTR may impede 
peripheral neuron signaling and enhance central neuron signaling [21]. Indeed, a study looking at 
peripheral nerve signaling in CF patients found 56% of patients had at least one abnormal signal, 
 6 
which was typically a reduced sensory nerve action potential [22]. CFTR has also been shown to 
affect intervention of peripheral nerves and the development of the central nervous system [19,21]. 
In CF human fetal tissue, CFTR dramatically increases in expression during fetal development in 
the cerebral cortex, ventricular zone and cortical plate [20]. Though overall, cerebral development 
is not affected by mutations in CFTR, with only a slight delay in maturation of the neuroepithelium 
and choroid plexus [20]. 
Intriguingly, both CFRD and microbiome diversity are associated with airway function, 
which is the primary cause of morbidity in CF patients [18,23,24].  Airway ciliated epithelial and 
submucosal cells harbor CFTR in their apical membranes where it acts as the primary route for 
chloride and bicarbonate conductance [13,25,26]. Chloride conductance across the cell membrane 
acts to enhance water secretion, which poises CFTR as a key regulator of the airway surface liquid 
(ASL) pH, composition and volume [13,27]. Its bicarbonate secretion in particular is tied to airway 
mucus viscosity and clearance as the absence of HCO3- ions dampens mucociliary transport [28]. 
HCO3- ions also drive mucus solubilization by complexing with Ca2+ or H+ cations on mucins, 
exposing the proteins’ negatives charge and providing a repulsive force to drive mucus granule 
expansion and solubilization [29,30]. 
Other anion channels and exchangers in the plasma membrane of airway epithelial cells 
contribute to the regulation of the ASL and mucus viscosity. Calcium activated chloride 
conductance channels (CaCC) and the solute carrier 26 (SLC26) family of transporters contribute 
to chloride and bicarbonate transport, while also interacting with CFTR. CFTR has been shown to 
inhibit Ca2+ stimulated Cl- currents in CaCC channels, while solute carrier variants such as 
SLC26A3 and SLC26A9 share direct contact with CFTR via their C-terminal domain with CFTR’s 
phosphorylated R domain [13,31]. Recent studies have also found class II CFTR mutations affect 
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SLC26A9 anion secretion, which highlights the importance of CFTR to regulate anion secretion, 
ASL volume and mucus viscosity [32].  
Regulation of the ASL and mucus viscosity by anion secretion through CFTR is crucial to 
the health of CF patients as they ultimately affect the proficiency of mucociliary clearance, the 
primary innate immune response in the airways [33]. This ultimately leads to persistent infections 
over the life span and decreases in lung function measured by the forced expiratory volume in one 
second (FEV1) [34]. While Pseudomonas aeruginosa is the most common infection associated 
with CF patients, Staphylococcus aureus infections are more prevalent during adolescence [35]. 
Critically, these infections induce Th17 and Th2 immune responses within the lung creating mucus 
biofilms that promote antibiotic resistance over time [36–38]. This remains a critical field of 
investigation for CF treatment since bacterial infections are enhanced by viral co-infection and 
current small molecular modulators of CFTR function do not ameliorate all types of infections in 
CF patients [39–41]. In total, lack of CFTR ion absorption and secretion affects organ physiology, 
immunology and microbiology, ultimately leading to mortality due to decreased lung function.  
1.1.3 Current and future treatment of CF 
Treatment of CF has expanded greatly over the past several decades, with patients living 
until their mid-40s and even late 60s if they possess less severe mutations (Classes IV, V and VI) 
[7,8,42]. Upon the discovery of CF, most patients were treated for pancreatic insufficiency using 
exogenous pancreatic enzymes to increase absorption of fats and proteins [2]. Concomitantly, CF 
patients are advised to eat a high caloric diet rich in fat, salt and protein to offset malnutrition [43]. 
In severe cases of malnutrition, patents may require a gastrostomy enteral tube for direct delivery 
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of nutrients to the stomach [44,45]. Other groups are also working on methods to measure risk of 
malnutrition, which is associated with pulmonary function [46]. 
Before FDA approval of CFTR small molecule modulators, CF patients were still able to 
live past their teenage years due to multiple treatment strategies targeted at pulmonary function 
[2]. This includes physical hand-percussion starting at birth and elevates to wearing a high-
frequency chest wall oscillation (HFCWO) vest and applying a positive expiratory pressure (PEP) 
mask, which are designed to loosen mucus [47]. Adherence to these treatments varies, though 
randomized clinical trials are testing novel devices using sound waves, which do not require chest 
wall compression and may increase adherence [48]. To further disrupt mucus during these 
treatments, CF patients inhale hypertonic saline and DNAse enzymes (Pulmozyme, Genentech) 
that increase the fluidity of the airway-surface liquid (ASL) and breakdown viscous DNA released 
by neutrophils in the airway [49,50]. Aerosolized β-adrenergic bronchodilators (e.g. albuterol) are 
also administered during treatment to relax the airway smooth muscle cells and increase lung 
compliance. While albuterol has been shown to increase Cl- concentrations in sputum, other studies 
have found albuterol may decrease production of cAMP and reduce CFTR activation during 
treatment with CFTR modulators [51,52].  
The advancement of CFTR modulators has made the future bright for CF patients. These 
revolutionary small molecules were initially screened in primary human bronchial epithelial cell 
cultures from CF patients, where anion conductance and ciliary function served as end-point 
measures [8]. CFTR modulators are now used in combination and serve different purposes based 
on how they affect CFTR plasma membrane trafficking and anion conductance. The first FDA 
approved modulator (VX-770, Ivacaftor or Kalydeco) acts as a potentiator, meaning it increases 
the amount of time CFTR is open for conductance [53,54]. Its effects were most pronounced in 
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patients who possessed class II, IV and V mutations since CFTR is still trafficked to the plasma 
membrane, though lacks in number or gating function. In order to further apply modulators to the 
most common CFTR mutation (i.e. Phe508del), which prevents membrane trafficking and affects 
gating, new small molecules were found to increase CFTR protein in the plasma membrane 
(tezacaftor-VX-661 and lumacaftor-VX-809) [55,56].  
Combination of lumacaftor and ivacaftor (Orkambi) then became the first FDA approved 
modulator therapy for patients homozygous for Phe508del [54]. Though, patients heterozygous 
for Phe508del who possess mutations unresponsive to ivacaftor potentiation or result in lack of 
CFTR in the plasma membrane were not responsive (as measured by FEV1) to Orkambi treatment 
[57]. This led to further development of new correctors, of which elexacaftor in combination with 
tezacaftor and ivacaftor was successful in improving FEV1 and decreasing pulmonary 
exacerbations by 63% in patients heterozygous for Phe508del [58]. This led to the newest FDA 
approval of the combinatorial CFTR modulator coined TRIKAFTA (elexacaftor-tezacaftor-
ivacaftor), which may also eliminate lumacaftor’s pulmonary adverse side effects [54,59].  
While CFTR modulators have been shown to significantly enhance lung function and may 
also ameliorate pancreatic insufficiency, they do not cure CF patients and have limited effects on 
lung inflammation due to chronic and resistant infections [60,61].  In one study looking at the UK 
CF registry, ivacaftor treatment was associated with reduced infection from P. aeruginosa after 3-
years of treatment. While S. aureus infection was also reduced, this was seen only in the last two 
years of treatment, and infections with Burkholderia cepacian complex were not reduced [62]. 
Importantly, infection with resistant strains of P. aeruginosa or B. cepacian are a hallmark 
of end-stage lung disease in CF patients where lung transplantation is considered. Criteria for 
transplantation include an FEV1 <  30%, frequent exacerbations due to chronic infection and 
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increased oxygen requirements [63]. Studies have found patients with resistant P. aeruginosa 
infections have decreased survival following lung transplant, though two year post-transplant 
survival curves are comparable between patients with non-resistant or resistant P. aeruginosa 
infection and transplantation is still advised [64,65]. Conversely, CF patients with B. cepacian 
complex infection have greatly reduced survival within the first year, with one study finding only 
29% of patients with B. cepacian complex survived the first year after lung transplant [66]. Other 
comorbidities also affect whether a patient receives a lung transplantation, including malnutrition 
and CFRD. Though since these morbidities can be managed, they are often considered modifiable 
risk factors before transplantation [65]. In total, the average increase in lifespan for CF patients 
receiving a lung transplant in 2014 was 8.3 years, and as modulator therapies develop, the need 
for lung transplantation may be delayed in CF patients [67,68]. However, development of new 
drugs to target antibiotic resistant bacterial infections remains a major concern for CF patients.  
In order to address chronic and resistant infections, researchers are investigating novel 
combinations of already approved antibiotics that have synergistic effects against lung damaging 
B. cepacian infection [69]. However new combinatory antibiotics may not suffice to kill drug 
resistant microbes due to their protection in mucus biofilms. This has led to new formulations for 
the most commonly used antibiotic in CF patients: tobramycin. By encapsulating tobramycin with 
hypromellose, aerosolized particles do not bind together and drug delivery to lower airways is 
enhanced [70]. Other studies have combined tobramycin and other antibiotics by encapsulating 
these drugs in N-acetylcysteine, a mucolytic drug, which together inhibits growth of P. aeruginosa 
biofilms [71]. This has led to research in encapsulating antibiotics in other compounds such as 
neutral-charged polymeric nanoparticles that do not interact with negatively charged mucins [72]. 
Other therapies, such as cationic antimicrobial peptides, degrade the extracellular matrix (ECM) 
 11 
of bacterial biofilms and prevents microbial communication that confers drugs resistance [39].  
Since antibiotics must always keep up with bacterial evolution, the most fundamental way to treat 
CF patients is to target the mutation in CFTR.  
CF has been the desirable model to test the therapeutic efficacy of genetic therapy since it 
is a monogenetic disease where correction of one allele can reverse disease progression. In order 
to change CFTR gene expression, DNA or RNA must be introduced to the cell. This can be 
accomplished by a multitude of transport systems, including adenoviruses, adeno-associated 
viruses and non-viral vectors made up of polymers or liposomes [72,73]. The first clinical trial to 
open the door to genetic manipulation of CFTR utilized adenoviral delivery of cDNA encoding 
WT CFTR to the nasal epithelium in three CF patients [74]. While chloride conductance was 
enhanced in these patients, larger trials using adenoviruses delivered CFTR cDNA via aerosol 
delivery to the lungs or lobular instillation failed to show enhanced lung function, with some 
patients experiencing fever and increased sputum production [75]. These results, along with lack 
of expression of the coxsackie-adenovirus receptor in human airway epithelial cells, led to the 
investigation of adeno-associated viruses (AAVs). Engineered AAVs and other parvovirus 
capsids, such as human Bocavirus-type-1 (HBoV1), have higher tissue tropism and  have been 
shown to correct CFTR in mouse nasal epithelial cells, CF patient derived intestinal organoids and 
ferret airway epithelial cells [73]. While AAVs may have a higher transduction rate, clinical trials 
failed to show increases in lung function 30 days from AAV delivery of full-length CFTR cDNA 
[76,77].  
While viruses have co-evolved with mammalian cells for opportune transduction, non-viral 
delivery methods have several benefits including higher carrying capacity, scalability and are non-
immunogenic [72]. Though, delivery of CFTR cDNA to the nucleus of the cell using non-viral 
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cationic liposomes still proves challenging. Phase 2 clinical trials using this approach with delivery 
every 28 days for 1-year have shown only modest improvement in lung function and did not show 
increases in CFTR expression [78]. This has led to investigation of mRNA targeted approaches, 
which eliminate the need to enter the nucleus. The oligonucleotide eluforsen shares 100% 
homology to WT CFTR mRNA and increased expression and chloride conductance in human 
bronchial epithelial cell cultures and in a murine model of Phe508del CFTR.   
As of this year, phase 1 clinical trials showing its safety after inhalation of eluforsen in CF 
patients look promising [79,80]. The main caveat of both viral and non-viral delivery methods is 
the repetitive treatment to maintain full-length CFTR expression. This is countered by the 
advancement clustered regulatory interspaced short-palindromic repeats (CRISPR) and the 
CRISPR associated peptide-9 (Cas9) endonuclease, which enable correction of CFTR mutations 
before lung development in human induced pluripotent stem cell (hiPSC) organoids [81]. 
CRISPR/Cas9 corrected organoids serve as a translatable human model to test both genetic and 
small molecular modulator therapies. Patient derived organoids may also serve as a cell 
engraftment strategy for CF patients, which would reduce the dosage rate of genetic therapies  [82–
84]. 
1.1.4 Experimental models of CF 
Since the gene responsible for CF was identified in 1989, researchers have created an array 
animal models to study the molecular and cellular pathology of CF. Each of these in vivo systems 
has their benefits and draw backs, which has led to the standardization of ex vivo primary human 
cell and organoid cultures for testing pharmacologic and genetic therapies [8,85]. To recapitulate 
the disease pathology, CFTR knock-out (KO) mice, pigs, ferrets, rats and rabbits have been 
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developed. CFTR KO mice exhibit intestinal blockage similar to meconium ileus at birth seen in 
humans, but do not develop spontaneous lung infections, mucosal inflammation in the airway,  
pancreatic inflammation or liver pathology [86]. This is mainly due to alternative chloride ion 
channel expression in mice and their lack of respiratory bronchioles [85,86]. Though, transgenic 
mice possessing WT CFTR that over express the sodium channel ß-ENaC do develop spontaneous 
infections and mucosal inflammation, which is due to sodium and airway liquid hyperabsorption 
preventing mucociliary clearance [87]. However, it should be noted that the ubiquitously used 
C57BL/6J mice strain is responsive to Pseudomonas aeruginosa infection, which 80% of CF 
patients experience [88–90].  
Other than rodents, both pig and ferret CFTR KO models possess most of the human 
pathologies associated with CF. This includes pancreatic inefficiency and spontaneous lung 
infection at birth, which is due to their possession of respiratory bronchioles and submucosal 
glands within the airway [85]. While animal models provide important organ system insights, the 
gold standard in modeling CF is cultured primary human bronchial epithelial cells (HBECs) since 
they possess patient specific CFTR mutations and other potential genetic or environmental factors 
relevant to CF pathology [91]. Obtaining HBECs is challenging to due extensive processing and 
delays in CF patient lung transplants due to CFTR modulator therapies [67]. Although when 
HBECs are isolated from lung tissue and cultured in factor supplemented media, these cells can 
be differentiated into pseudostratified monolayers with beating cilia [92]. Differentiation is 
supported by addition of extracellular matrix components and by culturing primary HBECs on air-
liquid interface (ALI) filters [91,93]. As well, coculture with other cell types, such as fibroblast, 
enhance cell passaging and doubling rates [92]. Since primary HBECs are hard to come by, 
researchers also use CF patient derived iPSCs. These stem cells can be easily stored and passaged 
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with the ability to differentiate into multiple tissue types [82,94]. This had led to their utilization 
in studying CFTR function in response to both genetic and pharmacologic treatments [81,83,95]. 
1.2 Asthma 
1.2.1 Genetic and environmental factors of asthma 
1.2.1.1 Genetic factors  
Asthma is a chronic inflammatory airway disease characterized by airway 
hyperresponsiveness and obstruction, where both genetic and environmental risk factors contribute 
to disease severity. Hundreds of genes have been identified to be associated with asthma, which is 
anywhere from 35 to 95% heritable [96]. In order to better understand which genes may play a 
more significant role in asthma, metanalyses of genome-wide association studies (GWAS) have 
tried to identify loci associated with airway obstruction. In the clinic, airway obstruction is 
measured by the forced expiratory volume in one-second (FEV1) and the ratio of FEV1 to the 
forced vital capacity (FEV1/FVC). These measures are associated with all-cause mortality, 
cardiovascular disease and asthma [97–99]. In one GWAS study, a cohort of 20,288 patients from 
14 different databases was screened for top loci associated with FEV1 or FEV1/FVC. This was 
followed-up by analyzing these hits against an additional 54,276 member cohort, which led to six 
loci associated with measures of airway obstruction [97].  These included HHIP, TNS1, GTSCD, 
HTR4, AGER (RAGE gene locus) and THSD4. In a separate meta-analysis of GWAS studies 
including 20,890 individuals, eight loci were significantly associated with FEV1/FVC and one was 
associated with FEV1 alone [98].  
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To determine these loci, both studies corrected for smoking exposure, which would greatly 
affect pulmonary function measures. Of note, loci identified in both studies included HHIP, HTR4, 
GSTCD and AGER [97,98].  The hedgehog-interacting protein (HHIP) gene was first implicated 
in airway obstruction in a GWAS study of over 7,000 individuals from Massachusetts [100]. Prior, 
HHIP was found to regulate branching lung morphogenesis. Absence of HHIP in mice leads to 
formation of only one right and left lung lobe and predisposes mice to developing airway 
obstruction when compared to WT mice [101,102]. The HTR4 gene codes for the 5-
hydroxytryptamine (serotonin) receptor 4, which is a G-protein coupled receptor. When serotonin 
is released from blood platelets, it acts on HTR4, increasing heart rate and vasoconstriction  [103]. 
Since serotonin was known to be elevated in asthmatic patients, in vitro studies using human 
airways showed serotonin binding to HTR4 induces airway constriction [104]. Serotonin is also 
found in cells of the innate immune system, including basophils and mast cells. Conversely, HTR4 
is found most highly expressed within the alveoli of the lung, which further implicates the 
serotonin system in immunity and lung function [105,106].  
GSTCD or glutathione s-transferase C-terminal domain-containing protein has been 
implicated in asthma based on its function in regulating oxidative stress. Based on structural 
homology to other GST enzymes, GSTCD has been proposed to function in oxidative stress by 
reducing reactive oxygen species, which protects DNA and proteins in the cell from oxidative 
damage [97]. Absence of GSTCD in mice predisposes these mice to developing lung cancer and 
non-cancerous lesions within the mucosal glands of the lung [107]. It is possible that SNPs within 
GSTCD may alter its enzymatic activity, thus promoting oxidative stress in the lung and worsening 
asthma symptoms [108]. Indeed, the SNP identified within GSTCD was highly correlated to FEV1 
compared to other genes identified in the meta-analysis [98]. 
 16 
The loci identified in the receptor for advanced glycation endproducts (RAGE, AGER-
gene) associated with FEV1/FVC leads to a glycine-to-serine (G82S) substitution in the receptors 
ligand binding V-domain [98,109,110]. Conversion from the non-polar to polar residue results in 
increased binding affinity of the RAGE ligand, enRAGE (S100A12), to G82S RAGE. When G82S 
RAGE is expressed in human polymorphonuclear cells, treatment with enRAGE  led to increased 
phosphorylation of MEK and MAP kinase enhancing proinflammatory cytokine production [109]. 
Since enRAGE is known to be elevated in asthmatic patients, this may explain how mutations in 
RAGE contribute to airway obstruction through enhanced signaling of RAGE ligands, which 
promote airway inflammation [111]. Indeed, studies from our lab have shown RAGE regulates 
type-2 allergic airway inflammation (AAI). Using RAGE-/- mice and primary human bronchial 
epithelial cells, previous studies have found RAGE regulates allergen induced IL-33 expression, 
innate immune cell recruitment, and production of IL-13, IL-5 and mucins, which are hallmarks 
of type-2 AAI [112–114]. Concomitantly, SNPs in IL-33 were found to be associated with asthma 
diagnosis in a meta-analysis across three ethnic groups, including European Americans, African 
Americans/African Caribbeans and Latinos [115]. While there are many loci attributed to 
pathological consequences of asthma, environmental factors including local environment, climate 
change and diet also have been found to have significant effects on asthma severity. 
1.2.1.2 Environmental factors  
Several environmental pollutants have been attributed to asthma pathogenesis through 
inflammation and cell death. These includes automobile fuel exhaust, ozone and particulate matter 
in the air [116]. Diesel exhaust particles (DEPs) are known to enhance Th17 immune cell activation 
and IL-17A production in primary human bronchial epithelial cells [117,118]. This finding is 
corroborated by increased expression of IL-17A in asthmatic patients who live near high traffic 
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areas compared to low traffic areas [118]. DEPs are also known to enhance type-2 AAI through 
release of IL-33 from the airway epithelium. Mice exposed to house dust mite (HDM) and DEPs 
accumulate IL-33 and produce type-2 proinflammatory cytokines. In contrast, mice lacking 
expression of the IL-33 receptor (ST2) stimulated with HDM and DEPs showed decreased levels 
of type-2 proinflammatory cytokines IL-13 and IL-5, as well as other markers of type-2 AAI [119].  
Ozone plays a role in airway inflammation, cell death and lung compliance. Ozone is 
formed from oxygen in the atmosphere reacting with volatile organic compounds and nitrogen 
oxide gases produced from fossil fuel exhaust. Ozone has been known to stimulate alveolar 
macrophages to produce proinflammatory cytokines, such as IL-6 and TNF-α [120]. IL-6 in 
particular is seen elevated in the bronchoalveolar lavage fluid (BALF) from asthma patients, and 
blockade of the IL-6 receptor in mouse models of asthma lower levels of type-2 cytokines 
[121,122]. Due to its powerful oxidation capacity, ozone induces the production of reactive oxygen 
species (ROS) in bronchial epithelial cells, which leads to cell death through activation of caspase-
9 [123]. ROS production due to ozone exposure has also been shown to decrease cilia formation, 
cilia beating and lung compliance measured by the end tidal volume and elastance [116,123]. In 
total, the impact of ozone on asthmatic patients is projected to lead to over 3,000 unnecessary 
emergency department visits between the years 2045 and 2055 due to climate change and weather 
patterns supporting ozone formation [124].  
Ultrafine carbon particles (<100 nm) and particulate matter (PM) are also increasing in the 
atmosphere due to the continual use of fossil fuels and coal. One study looking at non-smoking 
asthma patients exposed to air downstream of the airport LAX for only 2-hours found that ultrafine 
particles and airway traffic were associated with increased levels of circulating IL-6 or decreased 
FEV1 [125]. Interestingly, ultrafine carbon particles have also been shown to elevate IL-6 in 
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primary human bronchial epithelial cells [126]. While the bronchial epithelial cells responded to 
carbon particles by enhancing cytokine production, nasal epithelial cells exposed to carbon 
particles significantly lost their viability [126]. Mouse alveolar macrophages exposed to low 
concentrations of ultrafine particles have been shown to enhance proliferation, higher dosages 
induce caspase-8 mediated cell death [127]. These studies show particulate matter may 
differentially affect cells within the airway, and suggest exposure time and PM concentration alter 
the pathological consequences of PM exposure in asthmatic patients.  
Weather and seasonal patterns also affect asthma patients. Temperature changes are known 
to contribute to allergic symptoms, and cold dry air challenge can even be used to measure airway 
hyperreactivity and bronchoconstriction [116,128,129]. While other measures of weather 
including humidity, wind speed and precipitation have no founded direct effects on the airway, 
these factors play a role in the seasonal adaptation of plants. Plants require specific signals from 
weather patterns to initiate their lifecycle, and thus produce pollen.  Increases in global temperature 
and CO2 lead to plants producing pollen earlier, shifting their life cycle and even lengthening 
pollen production [130,131]. While allergic reactions to pollen is dependent on the plant species 
and length of exposure, pollen can react with air pollutants, such as ozone, creating more allergenic 
particles [132,133].  
Although many environmental factors contributing to asthma are found in the air, what’s 
for dinner can also affect the immune system and severity of asthma. The microbiome is composed 
of trillions of microorganisms, including bacteria, fungi and viruses, whose diversity and function 
are largely shaped by our diets as well as our parents’ diets [134]. During birth in both humans and 
mice, the microbiome is passed to offspring from the mother and can significantly affect the 
development of the immune system, particularly the spleen in mice [135,136]. Interestingly, obese 
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asthma patients compared to non-obese asthma patients have higher levels of eosinophils in the 
bronchoalveolar lavage fluid (BALF) and increased activation of IL-13 driven JAK-STAT6 
signaling that leads to mucin gene expression [137,138]. In the same study, it was found severe 
asthmatic patients had reduced levels of the bacteria A. muciniphila in their gut. After chronic 
challenge with HDM in mice, administration of A. muciniphila reduced eosinophils, neutrophils, 
T-cells and B-cells in the airway [137]. More global perturbations of the gut microbiome also play 
a role in asthma. Specifically, asthma diagnosis at the age of five is associated with increased usage 
of antibiotics along with a decrease in the diversity of the microbiome [139]. These studies suggest 
specific gut bacterial species, as well as overall microbial diversity, can have significant 
immunologic consequences in the lung.  
1.2.2 Pathophysiology of asthma 
Asthma is a heterogeneous chronic inflammatory disease of the airways involving the 
airway epithelium, connective tissue, endothelium, smooth muscle and the immune system. Over 
26 million Americans suffer from asthma and are estimated to lose 15.46 million quality adjusted 
life years between 2018-2038 [140]. Symptoms of asthma include, but are not limited to, 
wheezing, coughing, increased sputum production, airway obstruction and ultimately pulmonary 
exacerbations or “asthma attacks” [96]. The most common type of airway inflammation seen in 
asthma patients is type-2 allergic airway inflammation (AAI). This innate inflammatory response 
is centrally mediated by group-2 innate lymphoid cells (ILC2s) that receive molecular cues from 
the lung epithelium that drive their activation, expansion and abundant production of type-2 
proinflammatory cytokines [141].  
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Other types of innate lymphoid cells have also been discovered, including group 1 and 3 
innate lymphoid cells (ILC1 and ILC3s). All ILCs are derived from the same common bone 
marrow progenitor and become tissue resident immune cells that reside at mucosal barriers and 
surfaces in organs. Each express specific transcription factors (TFs) that define their functions in 
different forms of innate inflammation [142]. Specifically, ILC1s function in type-1 inflammation 
in response to bacteria and viruses, such as clostridium difficile (C. diff) and hepatis B [143,144]. 
They are activated by IL-12, IL-15 and IL-18 produced by macrophages and dendritic cells, and 
subsequently produce interferon gamma (INF-γ) [144,145]. ILC3s play a vital role in the gut by 
protecting the intestinal epithelium from microbial species by enhancing production of IgA, 
facilitating the formation of gut associated lymphatic structures and inducing intestinal stem cell 
repair [146,147]. ILC3s are activated by IL-1 produced by neutrophils and epithelial cells, and 
subsequently produce IL-17 and IL-22 [145]. ILC3s may also play a role in airway inflammation 
in asthma patients who do not have elevated levels of type-2 cytokines by inducing IL-8 production 
from lung epithelial cells though IL-17 signaling [148].  
Type-2 inflammation in the airways is activated by allergens, smoke, viruses or parasitic 
infections that stimulate airway epithelial cells to release cytokine alarmins such as thymic stromal 
lymphopoietin (TSLP), IL-25 and IL-33 [141,149]. Specifically, type-2 inflammation can be 
induced by viruses such as influenza A and Sendai virus leading to IL-33 production in the lung 
[150,151]. Parasitic infections such as infections with parasitic worms or helminths can also induce 
type-2 airway inflammation [152,153]. It has been assumed that type-2 immunity evolved due to 
prior evolutionary pressures from these organisms, which can be unintendedly activated by 
allergens such as house dust mite, Alternaria alternata (AA) or pollen [154]. However, there is no 
structural similarity in antigens present on helminths or allergens, nor are the reactions to helminths 
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and allergens similar in severity or time [155]. Thus, it has been proposed type-2 immunity evolved 
to protect from many types of environmental stimuli present in our evolutionary history.  
Antigen presenting cells, such as dendritic cells and alveolar macrophages play a key role 
in type-2 airway inflammation. These immune cells express major histocompatibility complex II 
(MHC-II) that binds to the foreign antigen and presents it to the T-cell receptor (TCR) expressed 
on CD4+ T-cells activating the adaptive immune system [156] (Fig. 1 B). Presentation of an 
allergic antigen by dendritic cells within the submucosa then induces the clonal expansion of T-
helper 2 (Th2) cells, which later differentiate into T-resident memory (TRM) cells that survive long-
term and readily produce type-2 cytokines upon the next exposure to an allergen [157]. CD4+ T-
cells can also clonally expand into Th1 cells, which react to antigens from intracellular parasites 
or bacteria [158]. Th1 cells produce type-1 cytokines such as INF-γ which activates phagocytosis 
by macrophages and helps regulate the balance of Th1 and Th2 responses, where lack of the INF-
γ receptor in mice results in enhanced Th2 responses [159]. Conversely,  activated Th2 cells 
produce the type-2 cytokine IL-4, which activates B-cells to go through Ig class switching to 
produce polyclonal IgE antibodies that bind with high affinity to the IgE receptor (IgER or FCεRII) 
expressed on mast cells and basophils [141,149,160]. Mast cells and basophils are now sensitized 
to the allergen, and upon a later exposure to the allergic antigen, IgE antibodies crosslink with the 
antigen and induce mast cells and basophils to degranulate, releasing histamines and proteases that 
induce an immediate type-2 hypersensitivity reaction characterized by vasoconstriction, vascular 
permeability and further immune cell infiltration [154,161–163] (Fig. 1 B). Mast cells and 
basophils have also been shown to produce type-2 cytokines, such as IL-4 and may play a role in 
the activation of Th2 cells [164].  
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ILC2s are activated by cytokine alarmins IL-33, IL-25 and TSLP and are responsible for 
the production of type-2 proinflammatory cytokines IL-5 and IL-13 from ILC2s  [165]. The release 
of cytokine alarmins is thought to occur by recognition of allergens by pattern recognition 
receptors, such as RAGE and Toll-like receptors [114,166]. These cytokine alarmins then activate 
ILC2s and facilitate type-2 airway inflammation by activating antigen presenting dendritic cells as 
well as CD4+ T-cells [154,167]. Type-2 proinflammatory cytokines IL-5 derived from either 
ILC2s or Th2 cells then lead to activation of eosinophils that release granule major basic protein, 
which can have damaging affects to the bronchial epithelial cells and contributes to the type-2 
hypersensitivity reaction [168,169]. Eosinophils may also communicate to the adaptive immune 
system through antigen presentation to naïve T-cells, furthering clonal expansion of Th2 cells 
[154].  
While type-2 airway inflammation is common in asthma, many patients do not possess 
elevated levels of type-2 cytokines. This has led the classification of asthma into endotypes based 
on the specific molecular pathology of a patient. Currently, Th2 “high” and Th2 “low” are used to 
broadly categorize patients [149]. Th2 “high” patients are characterized by elevated IgE in serum, 
increased IL-13 and IL-5 expression, elevated eosinophils within the blood and BALF, increased 
mucin gene expression and increased basement membrane thickens [170]. Th2 “low” asthmatics 
lack these profiles, are less responsive to bronchodilators and glucocorticoids, but display airway 
hyperreactivity and neutrophilic influx [148,170]. While the pathology of Th2 “low” airway 
inflammation is not fully understood, the Th17 immune response has been implicated in 
neutrophilic influx. Specifically, IL-17 produced by Th17 cells induces airway epithelial cells to 
release IL-8, which subsequently activates neutrophilic inflammation [148]. Though due to the 
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heterogeneity of asthma, more specific pathological categories exist, including early-onset mild 
allergic asthma, obesity related asthma and severe atopic asthma [171].  
Consequences of inflammation manifest in the airway and extrapulmonary organs. Within 
the airway mucosa, Th2 and Th17 cytokines induce mucous hyperplasia in humans and mucous 
metaplasia in rodent models of allergic airway inflammation [172–174]. Inflammation affects the 
airway submucosa by inducing smooth muscle cell hyperplasia, blood vessel development and 
deposition of extra cellular matrix (ECM) proteins [149]. This reduces the mechanical properties 
of the airways leading to fibrosis, constriction and obstruction [170,175,176]. Consequences of 
inflammation affecting the mucosa and submucosa ultimately lead to increased risk of a pulmonary 
exacerbations or “asthma attacks”, which is associated with mortality in asthma patients [99,177]. 
Outside of the airway, inflammation contributes to multiple comorbidities. These include  
inflammatory bowel disease (IBD), atopic dermatitis, obesity, and cardiovascular disease, which 
is associated with increased mortality in asthma patients [178–181]. In total, the severity of asthma 
is dependent on the degree of inflammation in the airway and other organs.  
1.2.3 Current and future treatment of asthma 
Treatments for asthma vary depending on a patient’s specific pathology and symptoms. 
Administration of β2-agonist (albuterol, levalbuterol etc.) and inhaled corticosteroids (fluticasone, 
budesonide etc.) are common and effective treatments for allergic or Th2 “high” asthma, though 
inhaled corticosteroids are not as effective for Th2 “low” asthma patients  [170,181]. β2-agonists 
act on the airway smooth muscle cells by binding to β2-adrenergic receptors, which reduces Ca2+ 
influx and muscle contraction, opening the airways [182]. Inhaled corticosteroids act on the airway 
vasculature as non-specific anti-inflammatories by reducing inflammation and angiogenesis [183].  
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While Th2 “low” asthmatics respond to β2-agonists, treatment with fluticasone does not enhance 
FEV1 when compared to placebo controls [170]. While the mechanisms driving Th2 “low” asthma 
have not been fully elucidated, smoking may be a confounding factor that reduces the effectiveness 
of corticosteroids and enhances neutrophilic inflammation in Th2 “low” patients [148].  
In more severe cases, patients presenting with pulmonary exacerbations due to an infection 
may require further treatment with systemic corticosteroids (prednisone, dexamethasone etc.) or 
ipratropium bromide  [181,184]. Treatment schedules using systemic corticosteroids vary and are 
controversial in the field due to their known side effects, including high blood pressure, ulceration 
of the gastrointestinal tract and mental illness [185]. Still, systemic corticosteroids have been found 
to reduce emergency room admission rates and are alone effective in reducing the relapse rate of 
pulmonary exacerbations [184]. Ipratropium bromide acts as a competitive inhibitor of cholinergic 
receptors, reducing constriction of airway smooth muscle cells. In combination with traditional β2-
agonists, it provides an synergistic effect on bronchodilation for patients dealing with severe 
pulmonary exacerbations and reduces side effects compared to albuterol alone [181,186].  
In order to more specifically treat asthma patients, clinical trials have focused on 
developing biologics targeting mediators of airway inflammation. These include monoclonal 
antibodies (mAbs) targeting a gamut of type-2 cytokines and their receptors, including IL-4, IL-
4Rα, IL-13, IL-13Rα, IL-5, IL-5Rα and TSLP [187]. mAbs raised to IgE (omalizumab), IL-5 
(mepolizumab and reslizumab) and the IL-4Rα/IL-13Rα complex (depilumab) have been FDA 
approved based on their ability to reduce pulmonary exacerbations, eosinophilia and the need to 
use corticosteroids [187–189]. While effective treatments for Th2 “high” patients, these treatments 
do not enhance lung function in patients with Th2 “low” asthma [187]. Since Th17 driven 
neutrophilia has been implicated in Th2 “low” asthma, clinical trials using mAbs targeting IL-17A 
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(secukinumab) and IL-17RA (brodalumab) have been conducted with limited effectiveness and 
consistency in improving lung function [148,187,190]. Thus, further investigation into the 
mechanism driving neutrophilia in Th2 “low” asthma patients is crucial.  
Other non-pharmacologic treatments have also been investigated for the treatment of 
asthma. Physical therapy, including breathing exercises and inspiratory muscle training, have been 
shown to decrease airway inflammation in asthma patients [191]. Metanalyses studying this effect 
have shown physical therapy reduces the incidence of asthma and can significantly improve the 
forced vital capacity (FVC) of asthma patients [192,193]. Dietary changes may also aid obesity 
related asthma patients by regulating the microbiome [137,179,194]. In one study using mice 
treated with house dust mite (HDM), a high fiber diet enhanced microbiome diversity and reduced 
Periodic acid Schiff (PAS) staining and the expression of IgE, IL-4 and IL-17 in the lung [194]. 
Natural substances, such as cannabidiol (CBD), can also reduce airway inflammation. In a mouse 
model using ovalbumin, intraperitoneal CBD was shown to reduce several markers of type-2 AAI, 
including IL-4, IL-5, IL-13 and eosinophil chemoattractant eotaxin-2 [195]. In summary, non-
pharmacologic treatments are advantageous to patients due to their inherent reduced cost and lack 
of serious side effects. Though, in order to most effectively treat asthma, clinicians should use a 
multifactorial approach including pharmacologic, biologic and integrative medicine treatments.  
1.2.4 Experimental models of asthma  
There are many experimental models for asthma which mimic the endotypes seen in 
patients. This primarily includes mouse models displaying elevated Th2 inflammation, Th17 
inflammation or a skewed response with both types of inflammation present [172]. While guinea 
pigs, rats, horses and non-human primate models have been also been used, these animals either 
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do not produce IgE as the primary anaphylactic antibody or do not lend themselves to genetic 
manipulation or immunological analysis [196]. Still mice do not naturally develop asthma, so 
various sensitization and treatment protocols have been developed. This includes administration 
of purified proteins or extracts from house dust mite (HDM), chicken egg ovalbumin (OVA), 
Alternaria alternata (AA), cockroach or ragweed to the airways of mice [196,197]. These allergens 
induce type-2 AAI in mice with treatment schedules ranging from 1 to 8-weeks to model an acute 
reaction [197,198]. Chronic reactions require month long treatments or involve transgenic animals 
that over express Th2 related cytokines, such as IL-9 or IL-13 [199].  An alternative mouse model 
uses adoptive transfer or intraperitoneal injection of allergen primed dendritic cells, which act as 
antigen presenting cells and lead to both Th2 and Th17 inflammation [172,200]. The 
intraperitoneal injection model is advantageous since it does not require anesthetization for 
treatment, which may reduce stress and variation of dosage between animals.  
Human bronchial epithelial cell lines and primary human bronchial epithelial cells 
(HBECs) are vital models for studying asthma. Bronchial epithelial cell lines, such as BEAS-2Bs 
or A549s, stimulated with allergens can model the Th2 inflammatory response [201]. While these 
submerged cell culture systems are readily available and easily maintained, they lack the physical 
characteristics of the airway (i.e. exposure to air), prior disease history of asthma and have altered 
responses to allergens when compared to primary HBECs [93,201,202]. Alternatively, primary 
HBECs isolated from asthma patients via bronchial brushings, biopsies or transplanted lung tissue 
have distinct cytokine and epigenetic profiles when compared to healthy controls, which may 
explain their difference to their cell line counterparts [203,204]. Primary epithelial cells can also 
be cultured on air-liquid interface (ALI) culture systems. This allows for their differentiation into 
a pseudostratified monolayer that possess beating cilia and goblet cells [92]. More complex culture 
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systems use three-dimensional scaffolds and co-culture of several primary epithelial cells types 
[93,205]. Though, since primary HBECs are hard to come by, several groups are studying 
embryonic development of the lung to differentiate human induced pluripotent stem cells (hiPSCs) 
into bronchial or alveolar epithelial cells [94,206–208]. These cells can then be seeded into three-
dimensional lung scaffolds or developed into organoids possessing secretory, basal and ciliated 
epithelial cells [95,209]. Thus, while primary airway epithelial cells are a highly translatable model 
to study asthma, the future of airway disease modeling lies in the development of hiPSCs into 
nearly identical structures as the lung.  
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2.0 The Receptor for Advanced Glycation Endproducts (RAGE) regulates mucus 
production & airway inflammation in models of Cystic Fibrosis 
2.1 RAGE 
2.1.1 RAGE structure and isoforms 
There are multiple RAGE isoforms produced by alternative splice sites within the RAGE 
gene (AGER). These isoforms are conserved across mammalian species and are differentially 
distributed within tissues and cell types [210–213]. To date, greater than 20 human and 17 murine 
isoforms have been classified in various tissues including the lung, brain and heart [214–216]. 
While many human variations exist, approximately 50% of these transcripts contain a premature 
stop codon and are not stably expressed due to nonsense-mediated decay [214].  
The most predominantly expressed transcript across species results in membrane-bound 
RAGE (mRAGE), which was discovered by Neeper et al. in bovine lung [210,217]. 
Posttranslational modifications produce a 45 kDa transmembrane protein with several domains, 
including a N-terminal signal sequence (aa1-22), a ligand binding V domain (aa22-116), two C-
type domains C1(aa124-221) and C2(aa227-317), a transmembrane domain (343-363), and a C-
terminal intracellular signaling domain (aa364-404) [110,210,214,218]. Interestingly, RAGE’s c-
terminal intracellular signaling domain does not contain a serine or threonine residue that can be 
phosphorylated [219].  
The most common transcript variant other than mRAGE, results in the production of 
soluble RAGE or sRAGE that lacks the transmembrane domain [214,215]. sRAGE acts 
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extracellularly to sequester RAGE ligands and prevent canonical RAGE signaling pathways 
[220,221]. sRAGE may also be derived proteolytically from mRAGE rather than by alternative 
splicing mechanisms, and sRAGE itself can be enzymatically cleaved to produce endogenous 
secretory RAGE (esRAGE) and cleavage RAGE (cRAGE) [222,223]. Other mRAGE isoforms 
lack portions of the ligand binding V-domain and  cannot transduce extracellular signals [110]. A 
newly discovered isoform of RAGE lacks the intracellular signaling domain and results in 
decreased downstream signaling [224].  
While RAGE isoforms are numerous, derived by different mechanisms, and vary from 
tissue to tissue, it is important to note mRAGE is highly expressed in the lung [211,217]. This has 
led to the implication of RAGE and its isoforms as regulators of inflammation in several lung 
diseases such as idiopathic fibrosis [220,225,226], cystic fibrosis (CF) [227,228], chronic 
obstructive pulmonary disorder (COPD) [229–232] and asthma [113,114,233,234].  Within the 
human lung, percentages of the two main isoform transcripts, mRAGE and sRAGE, have been 
estimated (80%; 7% respectively) [214]. Ratios of these two key isoforms change in the disease 
state and may serve as novel biomarkers in several lung diseases [230,235,236].  
2.1.2 RAGE ligands 
RAGE ligands include a diverse set of biomacromolecules, where increases in their 
concentration can induce RAGE expression and multimerization. This positive feedback-loop 
indicates RAGE is an amplifier in response to inflammatory signals [110,237,238]. Advanced 
glycation end products (AGEs) were the first ligands identified for the receptor, which are found 
in food, tobacco smoke and are produced endogenously in the body [210]. Endogenous AGEs 
accumulate over long periods of time through reactions between free amine groups on 
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biomacromolecules and reducing sugars. Alternatively, AGEs in food or cigarette smoke are 
thought to form quickly by thermal heating [239,240]. While RAGE can transduce AGE related 
signals, many other AGE receptors have since been identified [110].  
 Most RAGE ligands can be classified as damage associated molecular patterns (DAMPs), 
including HMGB1, S100 proteins, amyloid-β and nucleic acids [111]. DAMPs are molecular 
mediators of immune responses that target innate immune effectors like RAGE, Toll-like receptors 
and inflammasomes [241]. HMGB1 or amphoterin was first found to bind RAGE in the brain and 
regulates neuronal projections during cortical development [242,243]. It is now understood 
HMGB1 is a chromatin-binding protein released as a DAMP by activated immune cells or through 
cellular necrosis [237,244,245]. HMGB1 was first found to bind to RAGE, but also binds Toll-
like receptors (TLR2 and TLR4) due to shared motifs in the receptors’ N-terminal signaling 
domains [246]. The S100 family of proteins are intracellular calcium signaling peptides also 
associated with neuronal outgrowth like HMGB1, but are also implicated in inflammatory diseases 
due to their secretion by innate inflammatory cells [246–248]. S100A12 was the first isoform of 
the family found to bind RAGE and it mediates immune cell recruitment [243]. Many additional 
S100 family members, including S100B, S100A1, S100A6 and S100A12, have also been 
identified as RAGE ligands [218,248–250].  
Amyloid-β is yet another peptide DAMP recognized by RAGE. Amyloid-B acts as a 
neurotoxin in neurodegenerative diseases, such as Alzheimer’s disease [251]. Upon binding to the 
receptor, amyloid-β has been found to activate microglia in the brain, a key indicator of 
Alzheimer’s progression [252,253], and RAGE expressed in endothelial cells at the blood-brain 
barrier may contribute to amyloid-β transfer into the central nervous system [254]. RAGE isoforms 
have also been hypothesized to bind extracellular matrix (ECM) proteins from studies showing 
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RAGE overexpression in HEK293 cells promotes cellular extension on various ECM protein 
coated plates [255]. Indeed, RAGE has been shown to bind a diverse set of ECM proteins, 
including collagen I, IV and laminin, without additional scaffold proteins [256]. These direct 
interactions with the ECM may serve to regulate cell-to-matrix adhesion, though RAGE has been 
found to regulate cell-to-cell adhesion through binding β2 integrin protein (Mac-1) expressed on 
leukocytes [257]. These protein-protein interactions play an important role in immune cell 
migration to sites of inflammation. RAGE has also been shown to participate in protein-nucleic 
acid interactions during the inflammatory response. By binding both RNA and DNA, RAGE 
facilitates their uptake into endosomes in response to cell damage [238]. Even while there are 
many identified RAGE ligands, new molecules continue to be discovered, including pyridinoline, 
a molecule responsible for crosslinking collagen fibers [258]. 
2.1.3 RAGE signaling pathways 
Due to the receptor’s diverse ligands and expressional patterns, RAGE can induce an array 
of signaling cascades regulating inflammation, cellular differentiation, cell proliferation, migration 
and even cell death. The first evidence of RAGE inducing intracellular changes used AGE-albumin 
as a ligand, which increased the presence of proinflammatory reactive oxygen species (ROS), and 
led to the expression of the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) [259,260]. The activation of NF-κB was found to be triggered by ROS 
oxidation of p21RAS, which induced the mitogen activated protein kinases’ (MAPKs), ERK1 and 
ERK2 [260,261]. These pathways directly regulate the activation of NF-κB by inhibiting the 
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inhibitor of κB (IκB), which allows the transcription factor to enter the nucleus, bind to the RAGE 
promoter and activate RAGE transcription [110,262].  
MAP kinases were the first kinase family found to be activated by RAGE ligands, and 
share the Cdc42/Rac1 upstream pathway, which has been shown to be activated through 
Diaphanous-1 (Dia-1) binding to the receptor’s C-terminal signaling domain [263]. Specific 
ligands, such as HMGB1,  stimulate p38MAPK activation leading to muscle cell differentiation 
[264], and RAGE stimulated with S100B triggers MAP kinase kinases MKK4/7, which leads to 
c-Jun N-terminal kinase (JNK) induction of vascular cell adhesion molecule-1 (VCAM-1) found 
in aortic endothelial cells [265]. Our studies have also shown expression of VACM-1 is RAGE 
dependent in lung endothelial cells using RAGE knockout mice, which implicates RAGE as a 
mediator of immune cell recruitment in multiple tissues [113,266,267].  These MAP kinases have 
also been found to regulate metastatic glioma cell proliferation and migration through RAGE 
dependent mechanisms [268]. 
Other kinase cascades can regulate cell proliferation and migration and have been 
identified as targets of RAGE signaling. One pathway discovered in kidney cells showed AGEs 
can induce the activation of cyclin-D1 and cyclin-dependent kinase (Cdk) 4, which allows the cell 
to enter S-phase. This was transduced through the receptor tyrosine kinase, janus kinase (JAK) 2, 
and signal transducers and activators of transcription (STAT) 5 pathway, which promotes cell 
survival and proliferation by avoiding apoptosis [269–271]. STAT3 is another transcription factor 
that leads to cell proliferation through the oncogenic protein Moloney murine leukemia virus 
(Pim1) in vascular smoother muscle cells, where its activation was shown to be RAGE dependent 
using RAGE targeting small interfering RNA (siRNA) [272]. These findings suggest RAGE 
signaling affects the cell cycle through JAK/STAT pathways, which transforming growth factor-
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β (TGF-β) may concomitantly regulate with RAGE [273]. This axis between RAGE signaling and 
TGF-β has also been shown to promote cell migration through MAPKs ERK and p38 
phosphorylation of Smad 2/3 [274,275].  
The phosphatidylinositol-3 kinase (PI3K)-AKT pathway is also activated by RAGE ligand 
binding. It stimulates NF-κB, inducing expression of proinflammatory cytokines like TNF-α and 
IL-6 [276]. AGEs have been shown to activate the PI3K-AKT pathway by studies utilizing RAGE 
inhibitors such as FPS-ZM1 in murine kidneys [277]. Through NF-κB, the inflammatory response 
is set, activating the expression of TGF-β, IL-6, and promoting the accumulation of ROS, which 
are all dampened by RAGE antagonists [277,278]. These responses to ligand binding can then 
perpetuate the inflammatory response through the activation of NF-κB via ROS, inducing further 
RAGE expression [260,279].  
NF-κB activity is also increased when S100B proteins bind to RAGE, which has a pro-
survival effect by increasing the expression of Bcl-2. Though, higher concentrations of this RAGE 
ligand can induce cytochrome-c release from mitochondria, and thus apoptosis through activation 
of caspase-3 [247]. Indeed, RAGE may play a role in both anti-apoptotic and pro-apoptotic 
signaling depending on the species and concentration of the ligand present [280,281]. In total, the 
diverse effects of RAGE ligands on intracellular signaling begin to shed light on the receptor’s 
potential role as a co-receptor. Since RAGE shares pathways with other growth factor receptors, 
has the ability to multimerize, and leads to multiple cascades shared by some of its ligands, it has 
been hypothesized that RAGE is a co-receptor with serval other receptor families 
[246,273,274,282].  
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2.1.4 RAGE in CF type-2 airway inflammation 
Cystic fibrosis is a chronic autosomal recessive genetic disorder that leads to progressive 
loss of lung function due to mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) [283,284]. While patients experience a range of morbidities due to mutations in CFTR, 
including diabetes, malnutrition and liver disorders, respiratory failure and lung transplantation 
remain the main causes of death [8,11]. Patient lung function is frequently measured by the forced 
expiratory volume in one second (FEV1) and is associated with infection status and mucus 
viscosity [34,285]. 
In the lung, CFTR resides in the apical membrane of HBECs and regulates the airway 
surface liquid (ASL) volume, mucus viscosity and mucociliary transport [286]. Loss of these 
homeostatic functions due to CFTR mutations cause CF patients to experience recurrent infections, 
which increases mucus production, mucus plugging and pulmonary morbidity [34,287–289]. 
Recent studies have shown CFTR modulators that enhance channel presence and function decrease 
some types of infections, though therapies directly targeting mucus production, mucus plugging 
and airway inflammation are an active area of investigation to develop new therapeutics for CF 
patients [41,287,290].  
 Recent studies have revealed RAGE as a mediator of the type-2 airway inflammation by 
regulating mucus production and eosinophilic inflammation in both murine and human models 
[112,114,233]. RAGE knock-out mice stimulated with allergens or IL-33 have reduced 
accumulation of group-2 innate lymphoid cells (ILC2s) in the lungs [114]. These cells when 
activated produce type-2 proinflammatory cytokines Interleukin-5 (IL-5) and Interleukin-13 (IL-
13), which are key drivers of mucus production and eosinophilic airway inflammation 
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[138,291,292].  Thus, loss of RAGE prevents IL-13 driven mucus production and IL-5 driven 
recruitment of eosinophils to the lungs.  
Notably, both the type-2 immune response and RAGE are elevated in CF patients when 
compared to Non-CF controls [37,228]. In patients with CF, IL-13 and IL-5 are associated with 
the development of bronchiectasis, P. Aeruginosa infection and are elevated in the bronchoalveolar 
lavage fluid (BALF) when compared to Non-CF controls [37]. IL-13 and IL-5 are also found in 
viscous P. Aeruginosa mucus biofilms that approximately 80% of patients with CF develop [90]. 
Intriguingly, CF patient sputum shows increased levels of full-length RAGE protein and mRNA 
[228]. A single nucleotide polymorphism (SNP) in RAGE’s promoter region (rs1800625) 
identified in CF patients leads to increased expression of the receptor in vitro, and is associated 
with decreased FEV1% predicted in a cohort of 967 CF patients [293]. The proinflammatory 
RAGE ligand, S100A12 or enRGAE, is also found at high levels in CF airways, while anti-
inflammatory soluble RAGE (sRAGE) is found in low levels [227,249]. In addition, an increased 
ratio of enRAGE to sRAGE is correlated with decreased FEV1% predicted in CF patients [228].  
While RAGE regulates type-2 airway inflammation, and both are elevated in CF patients, 
studies inhibiting the type-2 immune response through RAGE in models of CF are lacking 
[287,290]. This led to the investigation of the role of RAGE in IL-13 induced mucus production 
and mucous hyperplasia in CF and Non-CF HBECs. Inhibition of RAGE signaling using the small 
molecule inhibitor FPS-ZM1 during IL-13 treatment blocks mucin gene expression, mucous 
hyperplasia, expression of mucous metaplasia transcription factors and the production of the 
chemoattractant eotaxin-2. Furthermore, knock-down of RAGE expression using dicer substrate 
siRNA (dsiRNA) in CF HBECs shows RAGE controls these various processes through activation 
of the signal transducer and activator of transcription-6 (STAT6). This study also investigated 
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RAGE’s role in an in vivo mouse model of P. Aeruginosa induced type-2 airway inflammation. 
After one week of intranasal treatment with P. Aeruginosa derived exotoxin, RAGE-/- had reduced 
mucus production when compared to WT treated mice. These studies indicate RAGE modulates a 
common form of airway inflammation associated with CF pathology.   
2.2 Materials and Methods 
2.2.1 Animals and reagents 
Twelve (6 female, 6 male) wild-type (WT) C57BL/6 mice were ordered from Taconic 
(Hudson, NY). An additional twelve age and gender matched RAGE-/- congenic C57BL/6 mice 
were obtained from an established breeding colony maintained under the University of Pittsburgh 
Department of Laboratory Animal Resources. All animals were aged to 7-weeks prior to 
experimentation. Animal studies were subsequently carried out under the National Research 
Council’s guidelines in the ‘‘Guide for the care and use of laboratory animals,’’ with oversight by 
the University of Pittsburgh’s Institutional Animal Care and Use Committee. 
2.2.2 Modeling type-2 airway inflammation in vivo 
Exotoxin derived from P. aeruginosa bacteria  was used to model type-2 airway 
inflammation in vivo based on several published protocols [88,89,294]. WT and RAGE-/- animals 
were treated every day for 1-week intranasally with 50 µl of 1 mg/ml exotoxin dissolved in 10% 
ethanol in water (experimental group) or 50 µl of 10% ethanol in water (control group). Mice were 
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then sacrificed 24 hours after the seventh treatment and the bronchoalveolar lavage fluid (BALF), 
whole lung homogenates and whole lung sections were harvested. BALF was obtained by 
perfusion and withdraw of 0.8 mL of 0.9% saline to both lungs through the trachea. The left lung 
was flash frozen using liquid nitrogen to obtain whole lung homogenates, and the right lung was 
inflated with 0.6 ml of 4% paraformaldehyde (PFA, Electron Microscopy Sciences) to obtain 
whole lung sections.  
2.2.3 Culture of primary human bronchial epithelial cells (HBECs) 
Primary HBECs were obtained from excess lung tissue under a protocol approved by the 
University of Pittsburgh Investigational Review Board (IRB). Random samples of both Non-CF 
and CF tissues were used for subsequent pharmacological and genetic knock-down experiments. 
Specific CFTR mutations and previous diseases states in CF and Non-CF samples, respectively 
can be found in table 1 of the appendix.  
To obtain HBEC cultures, bronchi were dissected, rinsed and incubated overnight at 4°C 
in MEM containing 0.1% type XIV protease (Sigma). The epithelial cells were isolated by 
centrifugation and washed in 5% FBS-MEM. After centrifugation, the cells were resuspended in 
serum-free bronchial epithelial growth medium (BEGM, Clonetics) and plated into collagen type 
IV coated t-25 flasks. After cells reached 80–90% confluence, they were trypsinized and 
resuspended in 5% FBS-MEM and seeded onto collagen type IV coated transwell filters for 
differentiation or onto 24-well plates to maintain their undifferentiated state (12 mm, Costar) at a 
density of 2x106 cells/cm2. After 24 hours, the medium was changed to DMEM-F-12 (1:1 volume) 
plus 2% Ultroser G (BioSepra). Apical media is removed to create an air-liquid interface (ALI) 
[92]. Media in the basolateral surface was then changed every 48 hours for 2-4 weeks until cells 
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were differentiated to polarized, ciliated cells. Differentiated cells were then used for 
pharmacological inhibition and imaging experiments, while cells in the undifferentiated state were 
used for genetic knockdown experiments. In both cases, Non-CF and CF HBEC samples were 
paired randomly for experiments based on what samples were available at the Lung Tissue Core 
at the University of Pittsburgh.  
2.2.4 Modeling airway mucus production in vitro 
To induce mucus production in vitro, human recombinant IL-13 (rIL-13, Biolegend) was 
used to stimulate induction of mucin gene expression, eotaxin production and mucous hyperplasia 
in HBECs [291,292]. Before rIL-13 stimulation, HBECs were differentiated in air liquid interface 
(ALI), which mimics the native condition of epithelial cells within the bronchus [295]. Cells 
exhibit moving cilia and produced a layer of mucus, both indicators of successful differentiation 
[92]. 
2.2.5 Pharmacological Inhibition of RAGE  
RAGE singling was inhibited by adding FPS-ZM1 (Millipore), which targets RAGE’s 
ligand binding V-type domain [296]. FPS-ZM1 was solubilized in DMSO (Sigma Aldrich) and 
added to fresh basolateral media of differentiated Non-CF and CF HBECs (50 µM). An equal 
volume of DMSO was dissolved in fresh basolateral media to act as the vehicle control in half of 
the samples. After one or three hours, rIL-13 (Biolegend) dissolved in 0.9% saline was added to 
the basolateral media of both RAGE inhibited and control HBECs (10 or 25 ng/ml). Control 
samples were treated with only 0.9% saline (2-5 µl) as the control for IL-13 treatment. After 48 
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hours, RNA, cell lysates and media supernatants were harvested. In extended experiments, RAGE 
inhibition and rIL-13 treatment were repeated at the 48-hour time-point. After 48 hours (96 hours 
from first treatment), RNA, cell lysates and media supernatants were harvested. 
2.2.6 Knockdown of RAGE expression using dicer substrate siRNA (dsiRNA) 
For knockdown of RAGE expression, Non-CF and CF HBECs were in an undifferentiated 
state to limit mucus production and enhance transfection efficiency [297]. HBECs were cultured 
in serum and antibiotic-free bronchial epithelial growth medium (BEGM, Clonetics). Cells were 
then transfected with RAGE targeted or control scramble dsiRNA (Integrated DNA Technologies) 
for 6 hours using Lipofectamine RNAi Max (Thermo). At 6 hours, media was changed to serum 
and antibiotic-free BEGM. After 20 hours post-transfection, cells were stimulated with rIL-13 in 
0.9% saline dissolved in the media at 10 ng/ml for 4 hours. Control samples were treated with only 
0.9% saline (5 µl) as the control for IL-13 treatment. Subsequently, cell lysates were harvested at 
24 hours using difference gel electrophoresis (DIGE) buffer (7 M urea, 2 M thiourea, 30 mM Tris, 
and 4% CHAPS) with 1X of the Halt protease and phosphatase inhibitor cocktail (100X, Thermo) 
on ice. Cell lysates as well as RNA were harvested to verify adequate knockdown of RAGE using 
RT-qPCR and western blot analysis. Samples were stored at -80°C until use. 
2.2.7 Quantitative RT-PCR 
HBEC RNA extraction after pharmacological or dsiRNA knock-down of RAGE 
expression was conducted using the RNeasy Mini Kit per the manufacturer’s instructions 
(QIAGEN). Primers used included human AGER (Hs00542584_g1), MUC5AC 
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(Hs01365616_m1), SPDEF (Hs00171942_m1), FOXA3 (Hs00270130_m1), CLCA1 
(Hs00976287_m1) and glyceraldehyde3-phosphate dehydrogenase (GAPDH) control 
(Hs02758991_g1) (Applied Biosystems, Foster City, Calif). Reverse transcription was performed 
with Moloney murine leukemia virus reverse transcriptase (Applied Biosystems, Foster City, CA) 
in a Techne thermal cycler (Bibby Scientific US, Burlington, NJ). Quantitative polymerase chain 
reaction (qPCR) was performed with universal PCR buffer and TaqMan primer/probe assay 
reagent (Applied Biosystems). The following cycling protocol was followed on an ABI Prism 7300 
machine (Applied Biosystems): 50°C (2 minutes), 95°C (10 minutes), and then 40 cycles of 95°C 
(15 seconds) followed by 60°C (1 minute). Fold change was then calculated compared with 
GAPDH mRNA control using the ΔΔCt method. 
2.2.8 Western blot analysis  
HBECs were lysed using DIGE Buffer with 1X of the Halt protease and phosphatase 
inhibitor cocktail (100X, Thermo) on ice. Total protein content was determined using a Bradford 
assay with bovine serum albumin (BSA, Fisher Scientific) and Coomassie protein assay (Thermo) 
or by the absorbance at 280 nm using a Nanodrop (Thermo). For gel loading, a mixture of 4X 
sample buffer (BIORAD) and 500 mM dithiothreitol (DTT) was prepared at a ratio of 9:1 and was 
subsequently mixed with 20-40 µg of HBEC protein at 1:3 ratio. Samples were then analyzed by 
SDS-PAGE on a 10% acrylamide gel (BIORAD) and subjected to immunoblotting. After blocking 
in 5% BSA-PBS, membranes were incubated in 1:1000 of primary rabbit anti-RAGE (Abcam, 35-
45 kDa), rabbit anti-STAT6 (Cell Signaling, 100-110 kDa), rabbit anti-pSTAT6 (Cell Signaling, 
100-110 kDa), and 1:5000 of primary mouse anti-β-Actin (Cell Signaling, 42 kDa) in 5% BSA-
PBS. This was followed by three 15-minute wash steps in tris buffer with 0.1% tween (T-BST) 
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and incubation for 1 hour in 1:5000 secondary horseradish peroxidase anti-rabbit or anti-mouse 
antibody (Jackson ImmunoResearch) in 3% milk. Membranes were washed as stated above and 
finally developed with chemiluminescent detection using ECL Plus Reagent (Thermo) before 
imaging (LI-COR Odyssey Fc). Densitometry was analyzed using Image Studio software (LI-COR 
Biosciences).  
2.2.9 Periodic-acid Schiff (PAS) Stain 
HBEC cultures and mouse whole lung sections were fixed with 4% paraformaldehyde 
(PFA, Electron Microscopy Sciences), paraffin embedded and cut into sections 4 μm thick (Pitt 
Biospecimen Core, University of Pittsburgh). Slides were then deparaffinized using xylene (Fisher 
Scientific) and rehydrated using decreasing ethanol (Fisher Scientific) concentrations (100%, 90% 
to 70% in MilliQ water). Slides were treated with periodic-acid solution, washed with MilliQ water 
and stained with Schiff’s regent before mounting with Permount media (Fisher). All slides were 
then examined by light microscopy. For PAS+ bronchial epithelial cells, total cell counts were 
recorded and the number of PAS+ cells or cells above the basal layer of cells where then divided 
by the total number of cells. The percentage of PAS+ airways was calculated by first counting all 
airways larger than 10 µm for each animal per treatment group. The number of PAS+ airways for 
each animal was then divided by the total airways in each animal and multiplied by 100% (n=5 
per treatment group).  
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2.2.10 Immunofluorescence (IF) imaging  
HBEC cultures were fixed with 4% paraformaldehyde (PFA, Electron Microscopy 
Sciences), paraffin embedded and cut into 4 μm thick sections (Pitt Biospecimen Core, University 
of Pittsburgh). Cells were then permeabilized with 0.3% Triton X-100, in 1% BSA-PBS for 10 
minutes at room temperature (RT). Between each step, 5 washes with 0.5% BSA-PBS were 
performed. Sections were blocked with 2% BSA-PBS for 45 minutes at RT. Primary antibodies 
were incubated at 4° C for 60 minutes, while secondary antibodies were incubated in the dark at 
RT for 60 minutes. RAGE and MUC5AC were labeled using primary rabbit anti-RAGE (Abcam) 
at 1:200 in 0.5% BSA-PBS and mouse anti-MUC5AC (Abcam) at 1:200 in 0.5% BSA-PBS. 
Fluorescent labeling was conducted using secondary goat anti-rabbit IgG at 1:500 (546 nm) and 
goat anti-mouse IgG1 1:500 (488 nm) dissolved in PBS. Slides were then washed 5 times in PBS 
and stained with DAPI at 2.5 µg/ml for 10 minutes (Thermo). Isotype controls were performed on 
separate slides using mouse IgG1, kappa monoclonal antibody and rabbit IgG monoclonal 
antibody (Abcam) with previously mentioned species-matched secondary antibodies. Sections 
were mounted with Prolong Diamond mounting agent (Thermo) and examined by an Olympus 
IX71 inverted microscope (Olympus, Tokyo, Japan). All images were processed with ImageJ 
software (NIH). In all cases a rolling ball radius of 50.0 pixels was used. 
2.2.11 ELISA for Eotaxin-2 
HBEC media supernatants were harvested after bulk media was pelleted at 4° C for 10 
minutes at 10,000 RPM. Subsequently, 100 µl of supernatant from each treatment group was 
loaded onto a 96-well plate and incubated with human Eotaxin-2 capture antibody per the 
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manufacturer’s instructions (R&D Systems). Absorbance was then measured after following the 
manufactures protocol with a plate reader at 450 nm to determine the concentration of Eotaxin-2 
in the media supernatant (Molecular Devices).  
2.2.12 Statistical Analysis 
Statistics were performed with GraphPad Prism 8 software (GraphPad Software, La Jolla, 
CA). Results are expressed as means of three to four HBEC trans-well filters from the same patient 
sample. For RT-qPCR, each trans-well (three to four replicates) was ran in duplicate before 
calculating the fold change and conducting the statistical analysis. For immunoblots, cell lysates 
were run in duplicate or triplicate and expression was quantified using densitometry (Image 
Studio). Statistical significance was determined using Student’s T-test or 2-way ANOVA/3-way 
ANOVA followed by Bonferroni’s multiple comparisons test based on the number of independent 
and dependent variables compared in each experiment (p<0.05 was considered significant). For 
the 3-way ANOVA used to look at gene expression from HBECs (Fig. 3, 6), a Brown-Forsythe 
test conducted in the GraphPad Prism 8 software was used to test for equal variance (Fig. 30-32). 
The Brown-Forsythe test showed significant differences in variance for several groups. This 
finding indicates a Tukey post-hoc test could not be used. Thus, a Bonferroni’s multiple 
comparison test was used as a post-hoc test after 3-way ANOVA to analyze the three effects 
studied: CF, IL13 and RAGE inhibitor. 
Power analyses were conducted in Minitab (Trialware, State College, PA) to determine if 
there was adequate statistical power for the RAGE expression analysis (Fig. 2, 29 A), and to 
determine the sample size required for future RAGE inhibition experiments looking at 
phosphorylation of STAT6 (Fig. 9, 29 B). The biological difference used in the power analysis for 
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RAGE expression was determined to be a 50% difference in RAGE expression or a difference of 
.5-fold change normalized to GAPDH. For determining the sample size for RAGE inhibition 
experiments looking at pSTAT6, the biological difference was obtained from dsiRNA 
experiments, where a change of approximately 350-fold change of pSTAT6 normalized to β-Actin 
was found to be significant when RAGE expression was blocked using dsiRNA during rIL-13 
treatment (Fig. 10). For all figures and analyses, N is defined as the number of total samples, 
whereas n is defined as the number of samples in a particular treatment or conditional group.  
2.3 Results 
2.3.1 RAGE expression in CF vs. Non-CF HBECs 
RAGE mRNA and full-length protein are elevated in CF patient sputum, and a SNP found 
in the promoter region of RAGE (-429T/C) in CF patients leads to increased expression of RAGE 
in vitro [228,293]. This led to the hypothesis that CF HBECs may have increased RAGE expression 
compared to Non-CF HBECs. Using RT-qPCR, RAGE expression was analyzed in six different 
Non-CF and CF HBEC cultures. RAGE expression in primary CF HBECs is similar to Non-CF 
controls (Fig. 2). However, it was unknown if any of these samples contained the SNP found in 
the promoter region of RAGE associated with increased expression. RAGE expression also did not 
appear to be dependent on the CFTR mutation class or prior disease state of the Non-CF HBECs 
(Appendix table 1).  
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Figure 2: RAGE expression in differentiated HBECs 
Fold change of RAGE expression was normalized to expression of GAPDH in Non-CF (n=6) and CF HBECs (n=6) 
using the ΔΔCt method. Colors represent the specific CFTR mutation(s) of the CF HBEC sample labeled in the figure, 
if known. Results for each HBEC sample are expressed as means of three to four replicates from the same patient. 
Statistical significance was determined using an Unpaired Student’s T-test, p<0.05 was considered significant, N=12, 
n=6. 
2.3.2 Pharmacological inhibition of RAGE blocks mucus production and CF HBEC 
hyperplasia 
Prior studies have shown RAGE regulates the effects of IL-13, which induces mucin gene 
expression in mice and in primary HBECs [112,114,138]. While RAGE expression was not found 
to be elevated in CF HBECs, CF patients have increased levels of mucus and type-2 
proinflammatory cytokine IL-13 [37,288]. To understand the role of RAGE in IL-13 induced 
mucus production in CF, Non-CF and CF HBECs were stimulated with recombinant human IL-13 
(rIL-13) for 48 and 96 hours (Fig. 3 A).  
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Stimulation with rIL-13 significantly increased expression of MUC5AC at both 48 and 96 
hours. In several cases, CF HBECs were hyperresponsive to rIL-13 stimulation compared to Non-
CF HBECs (Fig. 3 B, D). In order to see if RAGE regulates rIL-13 induced mucus production, the 
small molecule inhibitor of RAGE, FPS-ZM1, was used to block the receptor’s ligand binding V- 
domain [296]. Treatment with FPS-ZM1 before rIL-13 stimulation significantly decreased 
expression of MUC5AC at both 48 and 96 hours in CF HBECs (Fig. 3 B-E). This suggests RAGE 
plays a significant role in mucin gene expression in CF HBECs and RAGE inhibition blocks their 
excessive response to IL-13 stimulation. 
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Figure 3: Mucin gene expression in differentiated HBECs 
Fold change MUC5AC expression was normalized to the expression of GAPDH in Non-CF (n=4) and CF HBECs 
(n=4) 48 or 96 hours post the first treatment. HBECs were treated with FPS-ZM1 dissolved in DMSO (50 µM in 
basolateral media) or DMSO as the vehicle control. One to three hours later, HBECs were stimulated with rIL-13 
dissolved in saline (10 or 25 ng/ml in basolateral media) or saline as the vehicle control. At the 48-hour time point, 
RNA was harvested (A, B-D) or HBECs were re-stimulated with FPS-ZM1 and rIL-13 and later harvested at the 96-
hour time point (A, E). Results for each HBEC sample are expressed as means of three to four replicates per one 
patient. Statistical significance was determined using a 3-way ANOVA, followed by Bonferroni’s Multiple 
Comparisons test, p<0.05 was considered significant, N=8, n=4. p<0.0332 (*), 0.0021 (**), 0.0002 (***), 0.0001 
(****). 
 
Mucus production was further assessed using Periodic-Acid Schiff (PAS) and 
immunofluorescent (IF) staining of Non-CF and CF HBEC cross-sections. HBEC cultures were 
first washed with PBS to eliminate any mucus present on the apical surface before conducting the 
96-hour treatment schedule (Fig. 3 A). Under control conditions, PAS staining revealed CF 
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HBECs produced dehydrated mucus whereas Non-CF HBECs had minimal apical mucus 
secretions (Fig. 4 A, D). After rIL-13 stimulation, Non-CF HBECs produced a significant amount 
of mucus compared to the control (Fig. 4 B). Though unlike the Non-CF cells, CF HBECs 
displayed a proliferative response to rIL-13 treatment developing gland like structures above the 
apical surface (Fig. 4 E). Indeed, prior studies have found IL-13 induces proliferation in both 
mouse and human primary airway cells [298,299]. Mucous hyperplasia in CF HBECs was 
quantified by the percentage of PAS+ cells and cells present above the apical surface (Fig. 4 G, 
H).  Subsequent RAGE inhibition with FPS-ZM1 blocked the increase of PAS+ cells in the CF 
HBECs (Fig. 4 E-H), indicating RAGE also mediates CF mucous hyperplasia. 
 
 49 
 
Figure 4: PAS stains of differentiated HBECs 
PAS stains of Non-CF and CF HBECs cross-sections during control conditions (A,D) rIL-13 stimulation (10 ng/ml) 
(B,E) and RAGE inhibition with FPS-ZM1 (50 µM in basolateral media) (C,F). Mucins stain in dark magenta and 
black arrows indicate mucous hyperplasia (E). Prior disease states of the Non-CF HBECs were interstitial lung disease 
(ILD) and rheumatoid arthritis (RA) (A). CFTR mutations for the CF HBECs were of class I (G542X) and II (ΔF508+) 
(D). The percentages of PAS+ cells (G) and cells above the apical surface (H) in CF HBECs were quantified by diving 
the total amount of PAS+ cells or total amount of cells above the apical surface by the total amount cells from each 
individual image shown in D-F. These percentages were then graphed using GraphPad. Images were taken at 200X 
magnification. Scale bars = 20 µm. N=2, n=1. 
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RAGE, MUC5AC and nuclei (DAPI) were then stained in the same Non-CF and CF 
HBECs cross sections under control conditions or rIL-13 stimulation with or without RAGE 
inhibition (Fig. 5). Images were taken separately of Non-CF and CF HBECs using fluorescence 
microscopy before merging DAPI, RAGE and MUC5AC images, respectively (Fig. 26, 27). In 
control conditions, RAGE was found to be expressed in the apical surface of the cells and within 
the mucus on CF HBECs (Fig. 5 A, D). This is supported by previous studies finding RAGE 
mRNA and protein levels are elevated in CF patients’ sputum when compared to Non-CF controls 
[228]. Upon rIL-13 stimulation, MUC5AC expression increased in Non-CF HBECs (Fig. 5 B). 
Nuclear staining of CF HBECs shows an increase in cell number during rIL-13 treatment with 
cells forming gland like structures that express RAGE (Fig. 5 E). RAGE inhibition eliminated the 
presence of these structures in the CF HBECs and decreased MUC5AC staining in the Non-CF 
HBECs (Fig. 5 C, F). Together, these images show RAGE is expressed within the apical surface 
of the bronchial epithelium, is present within mucus secretions, and may play a role in inducing 
mucous hyperplasia in CF HBECs. 
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Figure 5: IF images of differentiated HBECs 
IF images of Non-CF and CF HBECs cross-sections during control conditions (A,D) rIL-13 stimulation (10 ng/ml) 
(B,E) and RAGE inhibition with FPS-ZM1 (50 µM in basolateral media) (C,F). Primary antibodies used to target 
RAGE (red) and MUC5AC (green) were diluted at 1:100 ratio. Secondary antibodies, goat anti-rabbit IgG (546 nm) 
and goat anti-mouse IgG1 (488 nm) were dissolved in PBS at a 1:500 ratio. Nuclei were stained using DAPI (2.5 
µg/ml). White arrows indicate RAGE expression in mucus and in cell structures formed in CF HBECs after rIL-13 
stimulation. Prior disease states of the Non-CF HBECs were interstitial lung disease (ILD) and rheumatoid arthritis 
(RA) (A). CFTR mutations for the CF HBECs were of class I (G542X) and II (ΔF508+) (D). Images were taken at 
200X magnification. Scale bars = 20 µm. N=2, n=1.  
2.3.3 RAGE regulates expression of mucous metaplasia transcription factors 
IL-13 induced mucous hyperplasia and metaplasia are regulated by secreted factors and 
transcription factors (TFs). The induction of  mucous metaplasia begins by secretion of CLCA1 
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from the cell, which leads to activation of MAP kinase [292]. MAP kinase then activates 
expression of TFs SPDEF and FOXA3, which both positively regulate mucous hyperplasia and 
metaplasia in mice exposed to IL-13 [173,300–302]. In order to understand how RAGE regulates 
the increase of PAS+ cells seen in CF HBECs in response to rIL-13 (Fig. 4 E), RT-qPCR was used 
to analyze the expression of genes regulating mucous metaplasia during rIL-13 treatment and 
RAGE inhibition. This included the expression of upstream signaling protein CLCA1 and the TFs 
SPDEF and FOXA3 (Fig. 6).  
For Non-CF HBECs, only SPDEF and FOXA3 were upregulated during rIL-13 treatment 
(Fig. 6 A-C). When RAGE was inhibited during rIL-13 stimulation, expression of these TFs was 
significantly diminished. In only one experiment did Non-CF HBECs have significantly greater 
expression of SPDEF compared to CF HBECs during rIL-13 treatment (Fig. 6 B). In contrast, rIL-
13 significantly upregulated CLCA1 and FOXA3 in CF HBECs when compared to Non-CF HBECs 
(Fig. 6 A-C). Whether Non-CF or CF, when expression of these factors was upregulated during 
rIL-13 treatment, RAGE inhibition with FPS-ZM1 was able to significantly down regulate their 
expression. These results support our previous finding that rIL-13 induces an increase in PAS+ 
cells in CF HBECs (Fig. 4 F, G) and begin to uncover how RAGE may regulate mucous 
hyperplasia through the activation of TF expression. This led us to further investigate other factors 
RAGE may regulate during rIL-13 treatment in CF HBECs.   
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Figure 6: Expression of TFs regulating mucous metaplasia in differentiated HBECs 
Fold change of CLCA1, SPDEF and FOXA3 expression was normalized to the expression of GAPDH in Non-CF (n=3 
patients) and CF HBECs (n=3 patients) 48 (A, B) or 96 hours (C) post the first treatment (see Fig. 2A). HBECs were 
treated with FPS-ZM1 dissolved in DMSO (50 µM in basolateral media) or DMSO as the vehicle control. One hour 
later, HBECs were stimulated with rIL-13 dissolved in saline (10 or 25 ng/ml in basolateral media) or saline as the 
vehicle control. At the 48-hour time point, RNA was harvested or HBECs were re-stimulated with FPS-ZM1 and rIL-
13 and later harvested at the 96-hour time point. Results for each HBEC sample are expressed as means of three to 
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four replicates. Statistical significance was determined using a 3-way ANOVA, followed by Bonferroni’s Multiple 
Comparisons test, p<0.05 was considered significant, N=6, n=3. p<0.0332 (*), 0.0021 (**), 0.0002 (***), 0.0001 
(****). 
2.3.4 Inhibition of RAGE reduces production of an eosinophil chemoattractant 
Signaling of IL-13 is not limited to the induction of mucus production and metaplasia. In 
models of asthma using allergens or IL-13 as a surrogate, bronchial epithelial cells respond by 
secreting high amounts of eotaxin-2 (CCL24) in the airway in response to IL-13 [233,291,303]. 
Prior studies show that RAGE inhibition with FPS-ZM1 significantly reduces levels of eotaxin-2 
in mice and primary human airway cells treated with IL-13 [112]. This chemoattractant recruits 
eosinophils into the lung, where they play a role in allergic inflammation by releasing reactive 
oxygen species (ROS) and inducing mucus production through release of IL-13 within the airways 
[304–306]. Intriguingly, CF patients have elevated levels of eosinophils and IL-13 within the 
airways during Pseudomonas aeruginosa infection or when compared to non-diseased control 
patients [36,37,90,307].  
ELISA was used to detect eotaxin-2 production in the extracellular media supernatants of 
Non-CF and CF HBECs treated with FPS-ZM1 and rIL-13. In response to rIL-13 treatment, Non-
CF and CF HBECs secreted eotaxin-2 into the extracellular media (Fig. 7). Notably, both CF 
patient samples secreted higher levels of the chemoattractant than either Non-CF sample (Fig. 7 
B, D). When RAGE was inhibited during rIL-13 treatment, Non-CF HBECs significantly reduced 
their production of eotaxin-2. In contrast, only one CF sample showed reduced eotaxin-2 
production during RAGE inhibition (Fig. 7 B). This shows RAGE regulates other IL-13 mediated 
eotaxin-2 production in the bronchial epithelium in addition to mucus production and hyperplasia. 
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These data again suggest CF HBECs are more responsive to rIL-13 treatment, enabling their ability 
to maintain secretion of eotaxin-2 during RAGE inhibition.  
 
Figure 7: Eotaxin-2 production in differentiated HBECs 
ELISA analysis of media supernatants from Non-CF (A, C) and CF (B, D) HBECs at 96 hours (N=4). HBECs were 
treated with FPS-ZM1 dissolved in DMSO (50 µM in basolateral media) or DMSO as the vehicle control. One hour 
later, HBECs were stimulated with rIL-13 dissolved in saline (10 ng/ml in basolateral media) or saline as the vehicle 
control. At the 48-hour time point, cells were again treated with FPS-ZM1 and rIL-13. Media supernatants were then 
harvested at the 96-hour time point. Results for each HBEC sample are expressed as means of four replicates. 
Statistical significance was determined using a 2-way ANOVA, followed by Bonferroni’s Multiple Comparisons test, 
p<0.05 was considered significant, N=4, n=3. p<0.0332 (*), 0.0021 (**), 0.0002 (***), 0.0001 (****). 
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2.3.5 Inhibition of RAGE reduces STAT6 phosphorylation 
To determine the signaling pathway involved in RAGE mediated mucus production, 
activation of the transcription factor (TF) known as the signal transducer and activator of 
transcription-6 (STAT6) was evaluated in Non-CF and CF HBECs. Activation via phosphorylation 
of STAT6 leads to the expression of MUC5AC, mucous metaplasia TFs and eotaxin-2  in models 
of type-2 airway inflammation [112,138,303]. Prior to activation of STAT6, IL-13 binds to the IL-
13Rα1 and IL-4Rα receptor complex leading to phosphorylation and Jak kinase activation. Jak 
kinase then phosphorylates STAT6, which enters the nucleus to induce the expression of its 
downstream targets including SPDEF, FOXA3, MUC5AC and CCL24 (eotaxin-2) [173,292,303] 
(Fig. 8). To understand if RAGE regulates phosphorylation of STAT6, Non-CF and CF HBECs 
were treated with rIL-13 or rIL-13 with the RAGE inhibitor FPS-ZM1 and whole cell lysates were 
harvested at 96 hours (Fig. 3 A). 
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Figure 8: IL-13 signaling pathway 
IL-13 binds to the IL-13Rα1 and IL-4Rα receptor complex leading to phosphorylation and Jak kinase activation. Jak 
kinase then phosphorylates STAT6, which enters the nucleus to induce the expression of its downstream targets. FPS-
ZM1 acts on RAGE and inhibits intracellular signaling, affecting STAT6 responsive gene expression.  
 
While there was STAT6 total protein in the vehicle control samples, no phospho-STAT6 
(pSTAT6) was detected in Non-CF and CF HBECs controls (Fig. 9 A). Upon treatment with rIL-
13, pSTAT6 was induced in Non-CF and CF HBECs. Using β-actin as a loading control, pSTAT6 
was then quantified in all three conditions (Fig. 9 B, C). Treatment with rIL-13 and the RAGE 
inhibitor, FPS-ZM1, results in a trend of reduced pSTAT6 in CF HBECs (Fig. 9 C). Conversely, 
no noticeable difference in pSTAT6 was seen in the Non-CF samples treated with rIL-13 and FPS-
ZM1 (Fig. 9 B). These results begin to suggest RAGE regulates mucus production, mucous 
metaplasia TFs and eotaxin-2 production in CF HBECs through phosphorylation and activation of 
STAT6. Several mouse studies modeling type-2 airway inflammation  have showed STAT6 plays 
a key role in IL-13 induced mucus production and airway inflammation [88,89,294].  As well, a 
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prior study shows wildtype mice have sustained activation of STAT6 when compared to RAGE-
/- mice treated with intranasal rIL-13 [112].  
 
 
Figure 9: STAT6 phosphorylation in differentiated HBECs 
Differentiated Non-CF and CF HBECs were treated with FPS-ZM1 dissolved in DMSO (50 µM in basolateral media) 
or DMSO as the vehicle control. One hour later, HBECs were stimulated with rIL-13 dissolved in saline (10 ng/ml in 
basolateral media) or saline as the vehicle control. At the 48-hour time point, cells were re-stimulated with FPS-ZM1 
and rIL-13. Cell lysates were then harvested at the 96-hour time point using phosphatase inhibitors to observe 
activation of STAT6. Gel electrophoresis and immunoblot were then conducted using primary antibodies for pSTAT6, 
STAT6 and β-Actin (A). Error bars represent the maximum value from the two replicate cell lysates per condition in 
the western blot. Densitometry was used to calculate the fold change for pSTAT6 normalized to β-Actin (B, C). 
Results for each condition are expressed as means of two replicates. N=2, n=1. 
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2.3.6 Knock-down of RAGE expression reduces STAT6 phosphorylation 
To further interrogate the role of RAGE in phosphorylation of STAT6, dicer substrate 
interfering RNA (dsiRNA) was used to genetically knock-down RAGE expression in 
undifferentiated primary HBECs. dsiRNA constructs were chosen to post transcriptionally silence 
RAGE expression due to their enhanced integration with the RNA induced silencing complex 
(RISC) and knock-down compared to traditional siRNA [308]. In addition, undifferentiated 
primary HBECs were used over differentiated cultures due to their enhanced transfection 
efficiency and absence of airway secretions that inhibit transfection of oligonucleotides [297]. 
Both Non-CF and CF primary cells were transfected with a non-targeted control dsiRNA (dsiCON) 
or a pool of three dsiRNA constructs to knock-down RAGE expression (dsiRAGE). Subsequently, 
these cells were treated with rIL-13 and cell lysates were harvested to see the effect of RAGE 
knock-down on phosphorylation of STAT6 (Fig. 10 A). 
Expression of RAGE was significantly downregulated in undifferentiated primary Non-CF 
HBECs when transfected with the pooled dsiRAGE constructs in undifferentiated primary Non-
CF HBECs (Fig. 10 B). These results were further confirmed by looking at RAGE protein 
abundance after transfection with dsiRAGE (Fig. 10 C, F). Quantification of RAGE protein 
abundance was normalized to β-Actin using densitometry and showed RAGE was significantly 
decreased in both Non-CF and CF HBECs using dsiRAGE (Fig. 10 D, G). To understand how loss 
of RAGE would affect phosphorylation of STAT6 in CF HBECs, dsiRNA transfected cells were 
treated with rIL-13 (Fig. 10 A). While rIL-13 induced phosphorylation of STAT6 in both Non-CF 
and CF dsiCON transfected cells, only CF HBECs treated with rIL-13 had significantly less 
pSTAT6 when RAGE protein was depleted (Fig. 10 E, H). These results support the previous 
finding that RAGE may regulate phosphorylation of STAT6 primarily in CF HBECs, which leads 
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to the induction of mucin gene expression, mucous hyperplasia and eotaxin-2 production (Fig. 9 
C) [292,303].  
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Figure 10: dsiRNA knock-down of RAGE expression in undifferentiated HBECs 
Undifferentiated primary Non-CF and CF HBECs were first transfected with either a non-targeted dsiRNA (dsiCON, 
100 nM) construct or a pool of three dsiRNA constructs targeted to RAGE expression (dsiRAGE, 100 nM). 
Transfection was carried out using RNAiMax in antibiotic free media for six hours, after which the media was changed 
(A). Cells were then treated with rIL-13 dissolved in saline (10 ng/ml in media) or saline as the vehicle control for 
four hours before RNA or cell lysates were harvested at 24 hours (A). RAGE mRNA expression analysis was 
conducted at this time point using RT-qPCR in non-diseased Non-CF HBECs and means represent six replicates (B). 
Cell lysates from Non-CF and CF HBECs were subjected to gel electrophoresis and immuno-blotting to detect protein 
abundance of RAGE, STAT6, pSTAT6 and β-Actin (C, F). Fold change expression of RAGE and pSTAT6 for Non-
CF (white, D, E) and CF HBECs (black, G, H) were calculated using Image Studio densitometry software and means 
represent three replicates for each culture condition. Error bars represent the standard deviation from the three replicate 
cell lysates per condition in the western blot. Statistical significance was determined using an Unpaired Student’s T-
test, p<0.05 was considered significant, N=2. p<0.0332 (*), 0.0021 (**), 0.0002 (***), 0.0001 (****). 
2.3.7 RAGE-/- mice have reduced mucus production in response to exotoxin derived from 
P. aeruginosa 
Since it is known RAGE modulates the effects of type-2 cytokines in the airway and a SNP 
in RAGE is associated with lung function indices (FEV1%) in patients with CF, it was hypothesized 
RAGE may regulate type-2 airway inflammation in response to exotoxin derived from P. 
aeruginosa [112,114,293]. In order to test this hypothesis, WT and RAGE-/- mice were treated 
with intranasal exotoxin, the primary immunogenic antigen present on P. aeruginosa. The 
bronchoalveolar lavage fluid (BALF) and lungs from these animals were analyzed for several 
markers of type-2 airway inflammation to determine if RAGE plays a role in exotoxin induced 
inflammation. 
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Control treated WT or RAGE-/- animals did not have a significant induction in mucus 
production or airway inflammation using PAS staining of whole lung sections (Fig. 11 A-H). 
Exotoxin treatment caused a significant increase in the percentage of PAS+ airways in WT 
animals, indicating mucus production (Fig. 11 Q). In several animals, there were significant signs 
of type-2 airway inflammation including large accumulations of mucus in the airway (Fig. 11 I), 
mucous hyperplasia (Fig. 11 J) and even bronchiolitis obliterans in one animal (Fig. 11 L). There 
were no PAS+ airways in the lungs of any RAGE-/- mice treated with exotoxin (Fig. 11 M-P, Q). 
Intriguingly, prior studies using exotoxin to induce airway inflammation found similar results in 
STAT6-/- mice. Even after intranasal treatment with exotoxin for three weeks, they found no 
airway inflammation in these animals [88]. These results support our findings in CF HBECs that 
RAGE contributes to the regulation of mucus production and the expression of mucus metaplasia 
TFs through activation of STAT6 (Fig. 9, 10).   
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Figure 11: Exotoxin treated WT and RAGE-/- mice 
Control WT and RAGE-/- animals were treated with 10% EtOH intranasally as the vehicle control following the same 
treatment schedule (N=20, n=5). Whole lung sections were then fixed and embedded in paraffin for PAS staining to 
detect inflammation and mucus production in the airways (A-P). Each image is from one animals and black arrows 
indicate sites of PAS positivity in the animals (dark magenta) (I-L).  An airway mucus score was then developed by 
calculating the percentage of PAS+ airways in each animal per the total amount of airways in each section (Q). Whole 
lung homogenates were collected to obtain RNA and subjected to RT-qPCR analysis to detect expression of Il-13 and 
Clca1 (R). The BALF from these animals was also collected to detect eotaxin-2 accumulation in the airways (S). 
Results for each treatment group are expressed as means of five animals. Statistical significance was determined using 
a 2-way ANOVA, followed by Bonnferoni’s Multiple Comparisons test, p<0.05 was considered significant, N=20, 
n=5. p<0.0332 (*), 0.0021 (**), 0.0002 (***), 0.0001 (****). 
 
Since P. aeruginosa infection is associated with elevated levels of IL-13 in the airways of 
CF patients, whole lung RNA was obtained to assess Il-13 expression in WT and RAGE-/- mice 
treated with exotoxin [36,37]. While Il-13 expression trended to increase in WT mice treated with 
exotoxin, RAGE-/- mice had no elevated expression of the proinflammatory cytokine (Fig. 11 R). 
Downstream, IL-13 signaling leads to expression of Clca1, a critical factor for the expression of 
mucus metaplasia TFs [292]. There was a similar trend of increased Clca1 expression in WT mice 
treated with exotoxin, though this was not found in RAGE-/- mice (Fig. 11 R). To further 
characterize the degree of airway inflammation in response to exotoxin, levels of the innate 
immune cell chemoattractant eoxtain-2 were analyzed in the BALF of WT and RAGE-/- mice 
treated with exotoxin. Eotaxin-2 production is induced by IL-13 signaling through activation of 
STAT6 [303]. There was no increase in eotaxin-2 production in the airways of RAGE-/- mice 
treated with exotoxin (Fig. 11 S). Combined, these results suggest RAGE may play a role in 
inducing the type-2 inflammatory response during P. aeruginosa infection. 
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2.4 Discussion 
 
In CF patients, RAGE mRNA and protein are elevated in the sputum when compared to 
Non-CF patients, and a SNP in RAGE is associated with decreased FEV1% predicted in CF 
patients [228,293]. Concomitantly, levels of type-2 proinflammatory cytokines IL-5 and IL-13 are 
elevated in CF patient airways and during P. aeruginosa infection [36,37]. This increases mucus 
production and airway inflammation in CF patients, which contributes to declining lung function 
over time [288,290,309]. While RAGE is known to regulate key steps of type-2 airway 
inflammation and is associated with CF, studies investigating how RAGE regulates this immunity 
in models of CF have not been conducted [112,114]. In this study, Non-CF and CF human 
bronchial epithelial cells (HBECs) were used to address how RAGE regulates the direct effects of 
the type-2 immune response using recombinant human IL-13 (rIL-13). In addition, we address if 
RAGE regulates type-2 immunity in vivo in response to P. aeruginosa derived exotoxin using WT 
and RAGE-/- mice. 
Based on our prior studies showing internasal treatment with IL-13 does not lead to mucus 
production in the airways of RAGE-/- mice, this study hypothesized RAGE may regulate the direct 
effects of IL-13, including mucus production and mucous hyperplasia in the bronchial epithelium. 
[112]. CF HBECs expressed significantly more MUC5AC than Non- CF HBECs and RAGE 
inhibition blocked this expression (Fig. 3). Concomitantly, PAS staining of HBEC cultures showed 
CF HBECs were hyperresponsive to rIL-13 treatment compared to Non-CF cells (Fig. 4, 5). While 
the CF bronchial epithelium is more responsive, there was no significant difference in RAGE 
expression between Non-CF and CF HBECs (Fig. 2).  
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This suggests while RAGE may not be elevated in CF HBECs, RAGE still contributes to 
mucin gene expression and mucous hyperplasia during rIL-13 stimulation. However, one CF 
HBEC sample (7, Appendix Table 1) possessing both severe classes of CFTR mutations (class I 
and class II) had the highest level of RAGE expression (Fig. 2; 1.69-fold change normalized to 
GAPDH) [8]. It would be interesting to investigate CFTR mutation effect on RAGE expression, 
though since there was only an N=1 for the CF sample with both severe classes of CFTR mutations, 
the specific CFTR class effect on RAGE could not be analyzed. With a sample size of only six, it 
is possible the two-sample Student’s T-test was not adequately powered to detect a significant 
difference between Non-CF and CF HBEC RAGE expression. Using a two-sample T-test based 
power analysis on these data (s=0.2048, α=0.05, n=6 per treatment group, biological 
difference=0.5-fold change normalized to GAPDH or a 50% difference in fold change), the power 
(1-β) was found to be 0.967 (Fig. 29 A). This indicates that while the sample size was low, the 
two-sample Student’s T-test was adequately powered to correctly reject the null hypothesis if the 
alternative hypothesis is true. Since the two-sample Student’s T-test determined the null hypothesis 
is true (there is no statistical significance between the two groups), it can be concluded there is no 
significant difference in RAGE expression between Non-CF and CF HBECs.  
In addition, this study found RAGE regulates the expression of key factors involved in 
mucous metaplasia in CF HBECs. CF HBECs significantly expressed more CLCA1 and FOXA3 
than Non-CF HBECs when treated with rIL-13 (Fig. 6 A-C). CLCA1 is critical for the expression 
of FOXA3 and both are activated by the transcription factor STAT6 [173,292]. CF cells also 
consistently induced expression of SPDEF in response to rIL-13, suggesting SPDEF plays a key 
role in the induction of mucus hyperplasia and metaplasia in CF [300,301]. Upon RAGE inhibition, 
the expression of CLCA1, SPDEF and FOXA3 were significantly down regulated. While RAGE 
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may not be elevated in CF HBECs, these cells are hyperresponsive to effects of rIL-13 through 
increased activation of CLCA1 and FOXA3 in a RAGE dependent manner. Since phosphorylation 
of STAT6 is upstream from the expression of these factors, it is also possible CF HBECs have 
sustained activation of STAT6 when compared to Non-CF HBECs [88,112].  
CF HBECs also produced more than double the amount of eotaxin-2 compared to Non-CF 
HBECs when treated with rIL-13 (Fig. 7). Inhibition of RAGE significantly reduced eotaxin-2 
production in both Non-CF and CF HBECS, though to a lesser extent in CF HBECs (Fig. 7 B, D). 
This indicates CF HBECs are more sensitive to IL-13 induced production of eotaxin-2, and that 
other pattern recognition receptors present in the bronchial epithelium may regulate production of 
eotaxin-2 alongside RAGE. Indeed, absence of Toll-IL-1 receptor 8 (TIR-8) in mice reduces 
expression of Il-13 and Ccl24 (eotaxin-2) during stimulation with house dust mite (HDM) [310]. 
Since eotaxin-2 is also regulated by activated STAT6, this study sought to understand how RAGE 
modulates the expression of mucins, mucous metaplasia TFs and eotaxin-2 by investigating 
activation of the upstream transcription factor STAT6.  
STAT6 is activated via phosphorylation by Jak kinases after IL-13 binds to the IL-13Rα1 
and IL-4Rα receptor complex [292]. To interrogate the role of RAGE in phosphorylation of 
STAT6 in CF HBECs, both pharmacological inhibition and dicer substrate siRNA (dsiRNA) 
knock-down of RAGE expression were used to block RAGE signaling during rIL-13 treatment 
(Fig. 9, 10). In Non-CF and CF HBECs, rIL-13 treatment induced phosphorylation of STAT6 
(pSTAT6) after 96 hours (Fig. 9 A). While Non-CF HBECs treated with rIL-13 and the RAGE 
small molecule inhibitor FPS-ZM1 maintained pSTAT6, a trend toward decreased pSTAT6 was 
seen in CF HBECs treated with rIL-13 and the RAGE inhibitor FPS-ZM1 (Fig. 9 C).  
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However, a statistical analysis could not be conducted on the decreased fold change of 
pSTAT6 normalized to β-Actin since there were only two samples per treatment group of CF 
HBECs. In order to determine how many samples would be required to correctly reject the null 
hypothesis (i.e. there is no significant difference between rIL-13 treated and rIL-13 with FPS-ZM1 
treated CF HBECs), a two-sample T-test based power analysis was used (s=90.95, α=0.05, 1-
β=0.85, biological difference=350-fold change normalized to β-Actin) (Fig. 29 B). This analysis 
found three samples (n=3) per treatment group are needed to correctly reject the null hypothesis 
and determine if RAGE inhibition with FPS-ZM1 blocks rIL-13 driven phosphorylation of 
STAT6. Thus, future studies should treat a minimum of three samples of CF HBECs with rIL-13 
and rIL-13 with FPS-ZM1. 
While this experiment was not adequately powered, it is interesting that Non-CF HBECs 
maintained rIL-13 driven pSTAT6 even during RAGE inhibition. This further supports the idea 
that bronchial epithelial cells may be reliant on other receptors than RAGE to activate STAT6 in 
response to IL-13, such as IL-4Rα or TIR-8 [292,310,311]. However, prior studies have shown 
Non-CF HBECs do rely on RAGE for activation of STAT6 [112]. This contradiction can be 
explained in part due to differences in the prior disease states or environments of patients where 
Non-CF HBEC samples were obtained, which have been shown alter expression of RAGE, its 
isoforms or other pattern recognition receptors such as Toll-like receptors [228,236,312]. Changes 
in receptor presence may ultimately affect subsequent downstream signaling, leading to either 
maintained phosphorylation of STAT6 or a decreased reliance on RAGE signaling for 
phosphorylation of STAT6.  
Phosphorylation of STAT6 was also assessed after confirming dsiRNA knock-down of 
RAGE expression was significant at the mRNA and protein level (dsiRAGE). Only in CF HBECs 
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did genetic knock-down of RAGE expression significantly deplete levels of pSTAT6 during rIL-
13 treatment (Fig. 10 B, F-H). It is worthwhile to note total STAT6 trended to decrease in response 
to dsiRAGE treatment (Fig. 10 C, F). However, this was not found to be a significant decrease 
using an unpaired Students T-test (Fig. 28). As well, in dsiRNA experiments carried out to 48 
hours, there was no noticeable trend of decreasing total STAT6 in response to dsiRAGE treatment 
(Fig. 25 B, C). dsiRNA experiments carried out until 48 hours also show CF HBECs do have 
sustained activation of STAT6 in response to rIL-13 treatment when compared to Non-CF HBECs 
(Fig. 25). Together, these results indicate CF HBECs may be more dependent on pSTAT6 than 
Non-CF HBECs signaling to induce the activation of mucin gene synthesis, mucous metaplasia 
TFs and eotaxin-2. This could be due to chronic activation of STAT6 since CF patients develop 
frequent lung infections and have elevated levels of IL-13 in their airways [36,37]. These data 
further corroborate CF HBECs hyperresponsiveness to rIL-13 treatment.   
To better link decreased STAT6 activation in CF HBECs with the effects of rIL-13, 
including mucin gene expression, expression of mucous metaplasia TFs and production of eotaxin-
2, it would be interesting to analyze these effects in CF HBECs treated with RAGE targeted 
dsiRNA. In this study, undifferentiated primary HBECs were used to enhance transfection 
efficiency [297]. Though to see how reduced RAGE expression affects mucin gene expression, the 
expression of mucous metaplasia TFs and the production of eotaxin-2, it would be necessary to 
knock-down RAGE expression in differentiated HBECs during rIL-13 treatment. This may require 
viral transduction of short-hairpin RNA (shRNA) to sustain knock-down of RAGE expression 
during the differentiation of HBEC cultures [92,313].  
The role of RAGE in inducing the type-2 immune response was also investigated during 
treatment with P. aeruginosa exotoxin. P. aeruginosa infection in CF patients is associated with 
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pulmonary exacerbations, decreased lung function and elevated levels of type-2 proinflammatory 
cytokines in the BALF [36,37,90,309]. Prior studies using intratracheal inoculation with P. 
aeruginosa in mice show RAGE-/- animals have reduced airway inflammation and cytokine 
production in the BALF, though they did not investigate type-2 cytokines or mucus production in 
these animals [314].   
Exotoxin is a tricyclic phenazine present on the P. aeruginosa membrane, which is elevated 
in mucus biofilms and CF patient sputum [88]. When strains of P. aeruginosa lack the ability to 
produce exotoxin, administrations with these species greatly reduces their ability to induce 
inflammation and pneumonia in the lungs of mice [88,315,316]. Since these and other studies have 
shown treatment with exotoxin alone in bronchial epithelial cells and in mice can induce the type-
2 immune response, WT and RAGE-/- mice were intranasally administered exotoxin for seven 
days [88,89].  
While exotoxin treatment in WT mice induced significant mucus production, mucous 
hyperplasia and even bronchiolitis obliterans, no signs of inflammation or mucus production were 
found in any of the lung sections from RAGE-/- mice treated with exotoxin (Fig. 11 I-Q). This is 
further supported by a lack of Il-13 and Clca1 expression in exotoxin treated RAGE-/- mice whole 
lungs (Fig. 11 R). RAGE-/- mice treated with exotoxin also trended to have depleted levels of 
eotaxin-2 in the BALF when compared to WT treated mice (Fig. 11 S). This suggest RAGE not 
only modulates the direct effects of IL-13 on the bronchial epithelium, but also plays a role in the 
most common infection CF patients develop. Importantly, studies using intranasal administration 
of exotoxin show STAT6-/- mice are protected from the proinflammatory effects of exotoxin [88]. 
Concomitantly, prior studies show RAGE-/- mice treated with IL-13 have reduced activation of 
STAT6 [112]. These previous finding along with this study further support the role of RAGE and 
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STAT6 in CF lung pathology. However, it would be valuable to extend the exotoxin treatment and 
determine if pSTAT6 is reduced in RAGE-/- animals.  
This study illuminates how RAGE plays a direct role in type-2 airway inflammation seen 
in CF. This is through modulation of the effects of IL-13 induced mucus production, mucous 
hyperplasia, mucous metaplasia TFs and eotaxin-2 production in CF HBECs. RAGE also 
facilitates mucus production in mice treated with intranasal exotoxin derived from P. aeruginosa. 
Both of these effects are likely modulated through activation of STAT6, though further RAGE 
inhibition experiments and shRNA knock-down of RAGE expression in differentiated HBECs are 
needed. However, prior studies have shown absence of RAGE reduces IL-13 induced activation 
of STAT6 over time in HBECs and mice, and absence of STAT6 reduces lung inflammation during 
exotoxin treatment [88,112]. In summary, RAGE may serve as a viable target for CF patients with 
an elevated type-2 immune response through direct regulation of STAT6.  
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3.0 IL-33 is not released from murine Type-1 Alveolar Epithelial Cells or Human Alveolar 
Organoids in vitro 
3.1 Interlukin-33 (IL-33) 
3.1.1 IL-33 structure and function  
IL-33 is a part of the interleukin-1 family of proteins and is a tissue derived nuclear 
cytokine expressed in multiple human tissues, including the lung [317]. It is translated as a 31-kDa 
protein (pro-IL-33, 270 aa) containing the IL-1 family consensus sequence (A-X-D) [318]. Full 
length IL-33 is biologically active and binds to the IL-1 receptor ST2 expressed on mast cells, 
endothelial cells and type-2 innate lymphoid cells (ILC2s) upon its release [317,319].  In the 
nucleus, IL-33 has been shown to bind heterochromatin and mitotic chromosomes in multiple 
human cell lines through its N-terminal helix-turn-helix domain [320].  IL-33 can regulate 
transcription in the nucleus, though upon its release during cell necrosis or allergen stimulation, 
IL-33 acts as a cytokine alarmin activating inflammation [202,321,322]. Interestingly, removal of 
IL-33’s N-terminal chromatin binding domain results in severe inflammation in both lymphoid 
and non-lymphoid organs in mice [323]. Thus, harboring IL-33 within the nucleus also acts to 
suppress inflammatory responses. 
When released, IL-33 drives type-2 allergic airway inflammation (AAI) in mucosal organs 
and  induces eosinophilia and production of type-2 proinflammatory cytokines, such as IL-5, IL-
13 and IL-4 [114,317,324]. This is through activation of ILC2s that produce these cytokines 
[165,325]. While other alarmins such as IL-25 can induce type-2 AAI, IL-33 is a more potent 
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inducer of immune cell proliferation and production of proinflammatory cytokines in models of 
asthma and chronic obstructive pulmonary disorder (COPD) [150,167,317]. This is corroborated 
by a single nucleotide polymorphism (SNP) flanking IL-33 (rs1342326) being associated with 
multiple subgroups of asthma patients, including child-onset, occupational, severe and adult-onset 
asthma [326].  
 Several studies have indicated released IL-33 is cleaved into different products depending 
on the initial stimuli. IL-33 has been shown to be cleaved by caspase-3 during apoptosis in both 
human and mouse cell lines. Though in comparison to models of necrosis, most of the cytokine 
remains inside the cell during apoptosis [321]. While prior studies showed IL-33 could be cleaved 
by inflammatory caspase-1, induction of inflammation did not result in cleavage of IL-33 by 
caspase-1 [317,321]. Allergen stimulation also induces cleavage of  IL-33 into multiple products 
based on proteases present within the specific allergen [327,328]. While these cleavage products 
varied in length and amino acid composition, all induced higher levels of type-2 AAI in vitro and 
in vivo when compared to full length IL-33 [327]. 
Since IL-33 and its cleavage products are potent inducers of type-2 AAI, it is imperative 
to understand how and in which cells IL-33 is released [167,327,328].  While some studies have 
shown allergens stimulate IL-33 release from human lung epithelial cells through an ATP 
dependent mechanism, it is still unknown how and where IL-33 is released in response to allergic 
stimuli [202,329]. This led to the investigation of which lung epithelial cell types are responsible 
for IL-33 release during allergen stimulation.  
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3.1.2 RAGE regulation of IL-33 in type-2 allergic airway inflammation 
RAGE is a member of the immunoglobulin superfamily and acts as a pattern recognition 
receptor by recognizing damaged associated molecular patterns (DAMPs) [110,210]. It recognizes 
DAMPS through its ligand binding V-domain, such as HMGB1, S100A12 and nucleic acids 
[250,330,331]. Since RAGE is most highly expressed within the lung epithelium, its ligands have 
been found to play a role in multiple lung inflammatory diseases, including asthma, COPD and 
cystic fibrosis [211,228,229]. 
Pulmonary function measures, such as the forced expiratory volume in 1 second (FEV1), 
are crucial tools to predict the severity and survival of individuals with lung disease, including 
asthma [99]. Importantly, a meta-analysis of three genome-wide association studies (approx. 
75,000 individuals) found a SNP in RAGE (rs2070600) associated with a measure of airway 
obstruction or the ratio of FEV1 to forced vital capacity (FEV1/FVC) [97,98,332]. This SNP leads 
to an amino acid substitution (G82S) in RAGE’s ligand-binding domain and enhances the binding 
affinity of the RAGE ligand S100A12, which induces mucus production in airway epithelial cells 
[109,250]. Moreover, S100A12 stimulation of primary human cells heterozygous for the G82S 
SNP enhances their production of proinflammatory cytokines, such as TNF-α and IL-6 [109]. 
Importantly, our studies found the receptor for advanced glycation end-products (RAGE) 
is required for IL-33 induced type-2 AAI in response to allergens house dust mite (HDM) and 
Alternaria alternata (AA) [114]. In WT mice treated with intranasal AA, production of IL-33 is 
significantly increased in the whole lung homogenates. Conversely, global RAGE-/- mice treated 
with AA do not upregulate production of IL-33. In allergen stimulated WT mice, IL-33 then 
induces proliferation and recruitment of ILC2s to the lung [167,325,333]. In subsequent studies, 
RAGE was found to be required for ILC2 recruitment to the lung through upregulation of vascular 
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adhesion factor 1 (VCAM1) [113,114]. ILC2s can then migrate to the lung from the vasculature 
and secrete proinflammatory type-2 cytokines, IL-5 and IL-13 [334]. These cytokines are known 
to play a critical role in the development of type-2 AAI by promoting mucus production, 
recruitment of eosinophils and mucous metaplasia [173,335–337]. While IL-33 and type-2 AAI 
are absent in the lungs of RAGE-/- mice, it is unknown how RAGE regulates IL-33 release and in 
what cell types this process occurs in. This led to the investigation of which lung cell types express 
RAGE and may release IL-33.   
3.1.3 Cellular localization of IL-33 release in the lung 
While many lung epithelial cells have been identified as IL-33 producing, type-1 alveolar 
epithelial cells (ATIs) neighbor the vasculature and highly express RAGE [338–340]. Our 
preliminary studies indicate primary mouse ATIs stably express RAGE in culture and release IL-
33 in response to Alternaria alternate (AA) (data not shown).  Other lung cell types, such as 
human bronchial epithelial cells (HBECs), have been shown to harbor IL-33 within the nucleus 
and release it extracellularly in response to allergens [202]. Using AA stimulation, Kouzaki et al. 
showed IL-33 is released extracellularly from HBECs after four hours.  
Contradicting these studies, other groups have not detected IL-33 in bronchial epithelial 
supernatants after allergen stimulation [201]. Using multiple allergens, including house dust mite 
(HDM), AA, Acetosella vulgaris (buckwheat) and Betula pendula (silver birch) Ramu et al. was 
not able to detect any IL-33 in the media supernatants. Further studies have identified lung basal 
cells, serous cells and type-2 alveolar epithelial cells (ATIIs) to harbor IL-33. These cells have 
been shown to upregulate IL-33 in models of influenza, COPD and aspirin-exacerbated respiratory 
disease (AERD), though not in models of asthma [150,151,341]. Though, while these cells may 
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express IL-33 in models of type-2 airway inflammation, these studies have not deduced if IL-33 
was released from these lung epithelial cells. 
It remains unclear which lung cell type both expresses RAGE and releases IL-33 in 
response to allergen stimulation. ATIs highly express RAGE and are positioned to induce type-2 
AAI by neighboring the vasculature for recruitment of ILC2s [340]. Concomitantly, variants of 
RAGE are associated with measures of airway obstruction and RAGE is required for allergen 
induced IL-33 production in the lung [97,109,114]. These studies have led to the hypothesis that 
RAGE mediates allergen induced IL-33 release from ATIs. To test this, primary murine ATIs 
isolated from WT and RAGE-/- mice were treated with AA to induce IL-33 release. In a second 
model, human induced pluripotent stem cell (hiPSC) derived alveolar organoids were treated with 
AA and IL-33 release was analyzed using ELISA.  
 
3.2 Materials and Methods 
3.2.1 Isolation of primary murine type-1 alveolar epithelial cells (ATIs) 
3.2.1.1 Lung perfusion and digestion  
Primary murine ATIs were isolated from both WT and RAGE-/- mice (N=12, n=6). 
Animals were first euthanized with 150 µl Pentobarbital (Henry Shein INC.) in PBS at a ratio of 
1:8. After opening the abdominal and thoracic cavities exposed the heart and lungs for perfusion, 
mice were exsanguinated by severing the vena cava, and lungs were perfused with 10 ml PBS. A 
20-gauge luer stub adapter was secured in the trachea with a suture, and lungs were inflated with 
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1.5 ml 37° C Solution B (40 ml RPMI (Gibco), 1ml of 1 M HEPES (Gibco), 4 g Dextran (Sigma) 
and 72 mg Elastase (Worthington)). Lungs were then separated from chest cavity and incubated 
by shaking in 3ml Solution B at 37° C. In a sterile hood, lungs were dissected using forceps into 
small pieces on TPP sterile plates (Sigma) for the cutting surface. Next, 3ml of DNAse Solution 
(40 ml RPMI, 1ml of 1 M HEPES, 2ml FBS and 4.5 µl DNAse-1 (Invitrogen)) was added before 
series filtration through 100, 70, 40 and 20 µm filters (Fisher Scientific). Filtrates were then 
pelleted at 350 RCF for 10 minutes at 4° C before being incubated for 5 minutes at room 
temperature (RT) in 3 ml Ammonium-Chloride-Potassium (ACK) red blood cell lysis buffer 
(Gibco). After lysis, 20 ml of 20% FBS-PBS was added to wash away the lysis buffer. Cells were 
then pelleted at 350 RCF for 10 minutes at 4° C and resuspended in 1 ml of 20% FBS-PBS and 
keep on ice before antibody labeling. 
3.2.1.2 Fluorescence-activated cell sorting (FACS) 
Ultra-Comp Bead (Invitrogen) single stain controls were used to compensate for spectral 
overlap during isolation of primary murine ATIs. Approximately 50 µl (one drop) of beads were 
incubated with 0.2 µg of each selection antibody, including BUV395 rat anti-Mouse CD45 (BD 
Biosciences), APC750 anti-mouse CD31 (BioLegend), Pacific Blue anti-mouse I-A/I-E or MHC 
class II (BioLegend) and APC anti-mouse Podoplanin or T1-α (BioLegend). Bead mixtures were 
then pulse vortexed and incubated on ice for 15 minutes, washed with 1 ml of 20% FBS-PBS and 
spun at 600 RCF for 4 minutes. Labeled beads were then resuspended in 200 µl of 20% FBS-PBS 
and kept on ice until the murine samples were labeled. 
From the main sample, two 50 µl aliquots were pulled for an unstained and dead cell 
control. Next, 10 µl of rat anti-mouse CD16/32 (BD Biosciences) was added to the main sample 
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and incubated on ice in the dark for 10 minutes. After washing in 10 ml of 20% FBS-PBS, the 
main sample was resuspended in 1 ml of 20% FBS-PBS and a third 50 µl aliquot was pulled for 
the fluorescence minus one (FMO) control. Cells were then counted in the main sample and FMO 
control before incubating with proper antibodies at a 0.25 µg/106 cells concentration. The main 
sample was incubated with all selection antibodies, whereas the FMO control was only incubated 
with negative selection antibodies (CD31, CD45 and MHC-class 11). Cells were then incubated 
on ice in the dark for one hour before washing and resuspension in with 1ml of 20% FBS-PBS. 
Lastly, 5 µl of 7-AAD Ghost Dye (TONBO Biosciences) was added to the main sample, FMO and 
dead cell controls before FACS isolation (United Flow Core, University of Pittsburgh). 
3.2.1.3 Culture of primary murine ATIs 
One day before isolation, a 24-well plate was coated with matrigel matrix at 0.768 mg/ml 
(Corning) in a 1:5 ratio with ATI media (40 ml DMEM (Gibco), 10 ml FBS and 0.5 ml 100X 
penicillin-streptomycin (Gibco)) and 0.03 mg/ml rat type-1 collagen (Corning). After FACS, 
murine ATIs were then seeded onto matrigel coated plates at 5x106 cells/well. ATI media was 
changed every 48 hours and cells were expanded for 6-8 days before experimentation.  
3.2.2 Culture of human induced pluripotent stem cells (hiPSCs) and alveolar organoids 
The BU3 NKX2-1GFP hiPSC line, received from the Kotton lab, was derived from 
peripheral blood mononuclear cells (PBMCs) from a female donor [342,343]. This line was 
previously characterized and showed a normal karyotype [208].  BU3 NKX2-1GFP hiPSCs were 
maintained in feeder-free conditions using matrigel (Corning) coated 6-well tissue culture dishes 
(Costar). Cells were fed every 24 hours using in mTeSR1 medium (StemCell Technologies) until 
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they reached confluence. Sites of colony differentiation were dissociated using autoclaved pipet 
tips (Fisher Scientific) and washed with 1 ml PBS before being aspirated. Colonies were then 
passaged using gentle cell dissociation reagent (StemCell Technologies).  
Alveolar organoids were differentiated from the SPC2 hiPSC line derived from dermal 
fibroblasts (Kotton Lab, Boston University, Center for Regenerative Medicine (CReM)). 
Organoids were shipped live from the Kotton lab in four 75 µl 3D matrigel (Corning) droplets 
suspended in CK+DCI media. CK+DCI media was formulated using IMDM (Thermo), Ham’s 12 
(Cellgro), B-27 supplement (Invitrogen), N-2 supplement (Invitrogen), BSA (Fisher Scientific), 
Primocin (Invivogen), GlutaMAX (Thermo), ascorbic acid (Sigma), MTG (1-thioglycerol, 
Sigma), CHIR99021 (Wnt activator, Tocris), rKGF (R&D Systems), dexamethasone (Sigma), 
cyclic-AMP (8-bromoadenosine 3',5'-cyclic monophosphate, Sigma) and IBMX (3-isobutyl-1-
methylxanthine, Sigma) (Kotton Lab, Boston University, CReM). Upon receipt, alveolar 
organoids in 3D matrigel were centrifugated at 150 RCF for 2 minutes and resuspended in Dispase 
(Thermo) dissolved in DMEM (Gibco) at 2 mg/ml. Alveolar organoids were then incubated at 
37°C for 30 minutes, and spun down at 200 RCF for 4 minutes. After removal of dispase, organoids 
were resuspended in 1 ml of 0.05% trypsin (Gibco) in DMEM and transferred to a 12-well plate 
for incubation at 37°C for 5 minutes. The single cell suspension was then added to 1.5 ml conical 
vials and pelleted at 300 RCF for 5 minutes. Cells were resuspended in CK+DCI with 10 µM Y-
27632 (Rho-associated kinase inhibitor, Tocris) to inhibit apoptosis, centrifuged at 300 RCF for 5 
minutes, resuspend in 3D matrigel and plated in a 12 well plate. After 72 hours of culture, Y-27632 
was removed from CK+DCI media. After eight days of culture, cells were characterized and 
subjected to allergen exposure.  
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3.2.3 Modeling allergen exposure in vitro 
To model type-2 AAI induction in primary murine ATIs and alveolar organoids, cells were 
exposed to the fungal allergen Alternaria alternata (AA) (GREER Laboratories INC). For primary 
murine ATIs, cells were treated with 50 µg/ml in ATI media for 6 hours. This is based on our own 
studies and others finding Alternaria is correlated with human asthma attacks, induces IL-33 
release from lung epithelial cells at 50 µg/ml between 2-8 hours, and increases IL-33 within the 
whole lung [114,202]. When considering alveolar organoids cannot reach confluency like primary 
alveolar cells due to their 3D culture conditions, a lower range of concentrations were used for 
type-2 AAI induction (0, 1, 5 and 10 µg/ml of AA dissolved in organoid differentiation media 
(CK+DCI) for 6 hours). 
3.2.4 Western blot analysis 
After murine ATIs were treated with AA, media supernatants were harvested after bulk 
media was centrifuged at 4° C for 10 minutes at 10,000 RPM. These supernatants were then 
concentrated using 0.5 ml, 3 kDa Pierce concentrators (Thermo) per the manufacturer’s protocol.   
Murine ATIs were then lysed using DIGE Buffer (7 M urea, 2 M thiourea, 30 mM Tris, and 4% 
CHAPS) with 1X of the Halt protease and phosphatase inhibitor cocktail (100X, Thermo) on ice. 
Samples were then stored at -80° C until analysis. Total protein content was determined for media 
supernatants and cell lysates using a Bradford assay with bovine serum albumin (BSA, Fisher 
Scientific) and Coomassie protein assay (Thermo). A mixture of 4X sample buffer (BIORAD) and 
500 mM dithiothreitol (DTT) was prepared at a ratio of 9:1 and was subsequently mixed with 10-
20 µg of murine ATI protein at 1:3. Samples were then analyzed by SDS-PAGE on a 10% 
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acrylamide gel (BIORAD) and subjected to immunoblotting. After blocking in 5% BSA-PBS, 
membranes were incubated in 1:1000 of primary antibodies, including mouse anti-IL-33 (Enzo 
Life Sciences, 30 kDa), rabbit anti-RAGE (Abcam, 35-45 kDa), rabbit anti-Auqaporin-5 (AQP5, 
Millipore Sigma, 28 kDa), rabbit anti-pro-Surfactant protein-C (proSPC, Millipore Sigma), mouse 
anti-Vimentin (Abcam, 54 kDa) and 1:5000 of primary mouse anti-β-Actin (Cell Signaling, 42 
kDa) in 5% BSA-PBS. This was followed by three 15 minute wash steps in tris buffer with 0.1% 
tween (T-BST) and incubation for 1 hour in 1:5000 secondary horseradish peroxidase anti-rabbit 
or anti-mouse antibody (Jackson ImmunoResearch) in 3% milk. Membranes were washed as stated 
above and finally developed with chemiluminescent detection using ECL Plus Reagent (Thermo) 
before imaging (LI-COR Odyssey Fc). 
3.2.5 Immunofluorescence (IF) and fluorescence microscopy 
3.2.5.1 IF: hiPSC characterization  
Human iPSC (hiPSC) were first cultured on matrigel (Corning) in a 12-well plate (Costar) 
on top of UV sterilized glass cover slips (Fisher Scientific) for seven days. Cultures were then 
fixed with 4% paraformaldehyde (PFA, Electron Microscopy Sciences) and permeabilized with 1 
ml of 0.3% Triton X-100 in PBS for 10 minutes at room temperature (RT). Between each step, 
three 5 minute washes were conducted using tris buffer with 01% tween (T-BST). hiPSCs were 
blocked with 4% goat serum-PBS for 30 minutes at RT (Vector Labs). Primary antibodies 
including mouse anti-cell-surface stage specific antigens (SSEA-1 and SSEA-4) and mouse anti-
keratin sulfate associated antigen (TRA-1-81) were incubated at 1:50 in 4% goat serum-PBS for 
one hour at RT (Millipore Sigma). Secondary antibodies including goat anti-mouse IgG (AF546 
nm) and goat anti-mouse IgM (AF488 nm) were incubated at 1:100 in PBS for one hour at RT 
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(Life Technologies). Slides were then washed as stated above and stained with DAPI at 2.5 µg/ml 
(Thermo). Cover slips were then mounted with gelvatol (Sigma) and imaged by an Olympus IX71 
inverted microscope (Olympus, Tokyo, Japan). 
3.2.5.2 Fluorescence microscopy: Alveolar organoid characterization 
hiPSC derived alveolar organoids were differentiated from hiPSC surfactant protein-C 
(SPC) cell line from Dr. Darrell Kotton (Boston University, MA). The SPC line expresses a 
tdTomato reporter allele before exon-1 of SPC to verify their differentiation to type-2 alveolar 
epithelial cells [208]. Alveolar organoids were then cultured in 75 µl droplets of 3D Matrigel 
(Corning) for 8 days before imaging by an Olympus IX71 inverted microscope (Olympus, Tokyo, 
Japan) under the tetramethylrhodamine (TRITC) channel to verify expression of SPC. 
3.2.6 ELISA for murine and human IL-33 
3.2.6.1 Murine IL-33 ELISA: Murine ATI media and lysates 
After murine ATIs were treated with AA, media supernatants were harvested after bulk 
media was centrifuged at 4° C for 10 minutes at 10,000 RPM. Murine ATIs were then lysed using 
DIGE Buffer as stated above. Subsequently, volumes of media supernatants and lysates from each 
treatment group were loaded onto a 96-well plate incubated with murine IL-33 capture antibody 
per the manufacturer’s instructions (R&D Systems). Following the manufactures protocol, 
absorbance was measured with a plate reader at 490 nm to determine the concentration of IL-33 
in the media supernatants and lysates (Molecular Devices). 
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3.2.6.2 Human IL-33 ELISA: Alveolar organoid media, matrigel supernatant and lysates 
After hiPSC derived alveolar organoids were treated with AA (50 µg/ml) for 6 hours, media 
supernatants were harvested after bulk media was spun down at 4° C for 10 minutes at 10,000 
RPM. 3D Matrigel droplets with alveolar organoids were washed three times with warm PBS and 
dissolved using Cell Recovery Solution (Corning) at 10X the volume of gel droplet for one hour 
on ice. Samples were then spun at 20 RCF for 5 minutes at 4° C. Matrigel was harvested from this 
supernatant, while organoids were washed twice in PBS at 20 RCF for 5 minutes at 4° C. The final 
cell pellets were lysed using DIGE Buffer (7 M urea, 2 M thiourea, 30 mM Tris, and 4% CHAPS) 
with 1X of the Halt protease and phosphatase inhibitor cocktail (100X, Thermo) on ice. 
Subsequently, undiluted volumes of media, Matrigel supernatant and organoid lysates were loaded 
onto a 96-well plate incubated with human IL-33 capture antibody per the manufacturer’s 
instructions (R&D Systems). Following the manufactures protocol, absorbance was measured with 
a plate reader at 490 nm to determine the concentration of IL-33 (Molecular Devices). 
3.2.7 Statistics 
Statistics were performed with GraphPad Prism 8 software (GraphPad Software, La Jolla, 
CA) for ELISA of murine and human IL-33. Means were determined from six to eight biological 
replicates per treatment group. Statistical significance was finally determined by using Student’s 
T-test or a One-way/2-way ANOVA followed by Bonferroni’s multiple comparisons test. A p-
value of less than 0.05 was considered significant from the multiple comparisons test where each 
treatment group was considered within the analysis. N is defined as the number of total samples, 
whereas n is defined as the number of samples in a particular conditional group. 
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3.3 Results 
3.3.1 Isolated primary WT and RAGE KO murine ATIs do not release IL-33 in response to 
Alternaria alternata 
Primary murine lung epithelial cells were isolated from WT mice to test the hypothesis that 
ATIs are responsible for RAGE dependent IL-33 release. After lung dissection and digestion, cells 
positive for T1-α were sorted (Fig. 12, pink). T1-α is a 40 kDa glycoprotein expressed in both 
humans and rodents [344]. This marker was used to sort murine ATIs since rodent in vivo studies 
have shown T1-α acts as a specific developmental biomarker for ATIs [345]. Approximately 1x106 
cells were sorted using T1-α (Fig. 12). 
After culturing these cells on matrigel containing rat type-1 collagen, they were then 
characterized using immunoblot for ATI specific markers. Interestingly, both control and AA 
treated cells expressed markers of ATIs, including aquaporin-5 (AQP5) and RAGE (Fig. 13) [255]. 
Though, these cells also expressed markers of type-2 alveolar epithelial cells (ATIIs) and 
mesenchymal cells, including pro-surfactant protein-C (proSPC) and vimentin respectively [339]. 
This was verified by looking at expression of these markers using whole lung homogenates (WLH) 
from WT and RAGE-/- (KO) mice (Fig. 13).  
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Figure 12: Initial FACS isolation protocol for primary murine ATIs 
Flow cytometry analysis shows cells positive for T1-α (pink) and negative for T1-α (royal blue) isolated from WT 
murine lungs. Cells were stained using APC anti-T1-α (pink) after being blocked with anti-mouse CD16/32. Six WT 
mice were used for the isolation protocol. Approximately 1x106 cells per total sample were isolated and cultured for 
further characterization. 
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Figure 13: Western blot of murine ATI markers 
T1-α isolated primary murine cells were cultured for seven days and treated with Alternaria (50 µg/ml) or control 
saline for 6 hours before cell lysates were harvested. Murine whole lung homogenates (mWLH) from WT and RAGE-
/- mice (knock-out, KO) served as the positive and negative control for RAGE labeling. Immunoblot for ATI markers 
(RAGE, AQP5), an ATII marker (proSPC) and mesenchymal cell marker (Vimentin) shows T1-α isolated primary 
murine cells express markers of all these cells types.  
 
The expression of vimentin and proSPC suggested the isolation protocol was not sufficient 
to isolate a pure population of murine ATIs. However, since other lung epithelial cells, such as 
ATIIs, increase IL-33 expression after exposure to influenza or Sedai virus, media supernatants 
from the mixed population of cells were analyzed for IL-33 [150,151]. While ELISA analysis 
showed a trend for the release of IL-33 after AA treatment, there was no statistically significant 
difference between the control and AA treated cell supernatants or lysates (Fig. 14 A, B)  
After finding the isolated murine lung cells were not pure and did not release IL-33 after 
allergen exposure, a new FACS isolation protocol was evaluated in an attempt to obtain a pure 
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population of ATIs. Using methods developed by Nakano et al. to isolate multiple cell populations 
from murine lungs, including ATIs, ATIIs, bronchial epithelium and endothelial cells, the protocol 
was altered to negatively select for endothelial cells and ATIIs [346] (Fig. 15 A, B). Antibodies to 
CD31 and MHC-II were used to negatively select for endothelial cells and ATIIs, respectively, 
since both of these markers are highly expressed in these cell populations [347]. This was followed 
by positive selection of ATIs using T1-α (Fig. 15 C).  
 
Figure 14: IL-33 release from primary murine lung cells 
WT primary murine lung cells were stimulated with 0 and 50 µg/ml of Alternaria in ATI media for 6 hours at day 7 
(D7) of their culture. Subsequently, extracellular media supernatants (A) and cells lysates (B) were harvested and 
subjected to ELISA for detection of murine IL-33 (n=3 for each sample). The dashed line at y=15.6 pg/ml indicates 
the detection limit. Statistical significance was determined using a Student’s T-test, p<0.05 was considered significant.  
 89 
 
Figure 15: FACS isolation of WT primary murine ATIs 
Flow cytometry analysis shows negative selection of cells positive for MHC-II (royal blue) (A) and CD31 (pink) (B), 
marking ATIIs and endothelial cells respectively, isolated from WT murine lung cells. Positive selection of cells 
expressing ATI marker T1-α (green) followed (C). Cells were stained with Pacific Blue anti-MHC-II, APC-Cy7 anti-
CD31 and APC anti-T1-α after being blocked with anti-mouse CD16/32. Six WT mice were used for the isolation 
protocol. Approximately 0.5x106 cells per total sample were isolated and cultured for further characterization. 
 
After employing the new isolation protocol, isolated WT murine lung cells were cultured 
on matrigel containing rat collagen-1 (Fig. 16). Cells displayed a morphology typical of ATIs, with 
a wide cytoplasm distributed around the nucleus, which facilitates their gas exchange function in 
vivo [338]. At day seven, cell lysates were harvested to determine ATI marker expression (Fig. 
17). Indeed, isolated murine lung cells expressed markers of ATIs, including AQP5 and RAGE, 
but do not express proSPC. This suggested the new isolation protocol was sufficient to obtain a 
pure population of ATIs. 
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Figure 16: Culture of WT primary murine ATIs 
After FACS isolation, WT primary murine ATIs were seeded onto matrigel coated plates at 5x106 cells/well. ATI 
media was changed every 48 hours and cells were expanded for 6-8 days before experimentation. Cells exhibit a round 
and broad morphology, indicative of ATIs, by day 6 (D6).  
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Figure 17: Western blot of murine ATI markers 
Isolated primary murine cells were cultured for seven days before cell lysates were harvested. Only control primary 
murine cell lysates were subjected to immunoblot. Murine whole lung homogenates (mWLH) from WT and RAGE-
/- (knock-out, KO) mice served as the positive and negative control for RAGE expression. Immunoblot for ATI 
markers (RAGE, AQP5), an ATII marker (proSPC) shows T1-α + isolated primary murine cells express markers of 
ATIs.  
 
The new protocol was then used to isolate both WT and RAGE-/- murine ATIs to test the 
hypothesis that RAGE is required for allergen induced IL-33 release. WT and RAGE-/- murine 
ATIs were isolated by using an additional negative selection for CD45 (Leukocytes) to further 
enhance purity of our population (Fig. 18, B pink). Cells where then positively selected for using 
T1-α (Fig. 18, D sky blue). After culture for six days, there was a low cell density in both WT and 
RAGE-/- ATIs compared to the prior isolation (Fig. 19). This is likely due to having three negative 
selection antibodies compared to only two (Fig. 15, 16).  
 92 
At day seven, WT and RAGE-/- murine ATIs were treated with 0, 25 or 50 µg/ml of 
Alternaria for 6 hours to test if RAGE was required for IL-33 release from these lung epithelial 
cells. Control treated cell lysates were used to determine ATI marker expression (Fig. 20). While 
adding a third negative selection antibody decreased cell confluency, isolated murine lung cells 
still expressed markers of ATIs, including AQP5 and RAGE, but not proSPC (Fig. 20). The 
extracellular media supernatants of WT and RAGE-/- ATIs treated with Alternaria were then 
analyzed for IL-33 release, but no detectable levels of murine IL-33 were found in either 
population (Fig. 21). 
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Figure 18: FACS isolation of WT primary murine ATIs 
Flow cytometry analysis shows negative selection of cells positive for MHC-II (royal blue) (A), CD45 (pink) (B), and 
CD31 (red) (C) isolated from WT murine lungs and RAGE-/- murine lungs (data not shown). Positive selection of 
cells expressing ATI marker T1-α (sky blue) followed (D). Cells were stained with Pacific Blue anti-MHC-II, 
BUV395 rat anti-CD45, APC-Cy7 anti-CD31and APC anti-T1-α after being blocked with anti-mouse CD16/32. Six 
WT and RAGE-/- mice were used for the isolation (N=12, n=6). Approximately 0.25-0.35x106 cells per total sample 
were isolated and cultured for further characterization. 
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Figure 19: Culture of WT and RAGE-/- primary murine ATIs 
After FACS isolation, WT (A) and RAGE-/- (B) primary murine ATIs were seeded onto matrigel coated plates at 
5x106 cells/well. ATI media was changed every 48 hours and cells were expanded for 7 days before experimentation. 
Most cells exhibit a round and broad morphology, indicative of ATIs, by day 6 (D6). 
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Figure 20: Immunoblot of WT and RAGE-/- murine ATI markers 
Isolated primary murine cells were cultured for seven days and treated with Alternaria (50 µg/ml) or control saline 
for 6 hours before cell lysates were harvested. Only control primary WT and RAGE-/- murine cell lysates were 
subjected to immunoblot. Murine whole lung homogenates (mWLH) from WT and RAGE-/- (knock-out, KO) mice 
served as the positive and negative control for RAGE labeling. Immunoblot for ATI markers (RAGE, AQP5), an ATII 
marker (proSPC) shows T1-α isolated primary murine cells express markers of ATIs.  
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Figure 21: IL-33 release from WT and RAGE-/- primary murine lung cells 
WT and RAGE-/- primary murine lung cells were stimulated with 0, 25 and 50 µg/ml of Alternaria in ATI media for 
6 hours at day 7 of their culture. Subsequently, extracellular media supernatants were harvested and subjected to 
ELISA for detection of murine IL-33 (n=3 for each group). The dashed line at y=15.6 pg/ml indicates the detection 
limit. Statistical significance was determined using a 2-way ANOVA, followed by Bonferroni’s Multiple Comparisons 
test, p<0.05 was considered significant. 
 
Since IL-33 was not able to be detected from murine ATIs using multiple isolation 
protocols, it appears these cells alone are not responsible for IL-33 release. It is possible a 
relationship exists between ATIs and other lung epithelial cell types, such as ATIIs, which have 
been shown to express IL-33 during allergen exposure [151,348,349]. To further explore the 
potential role of alveolar epithelial cells in IL-33 release during allergen exposure, a human model 
was employed, using human induced pluripotent stem cell (hiPSC) derived alveolar organoids. 
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3.3.2 hiPSCs express human pluripotency markers 
The hiPSC line NKX2.1-GFP were cultured and expanded to bank them for future 
differentiation to lung epithelial cell organoids using protocols developed by the Kotton Lab 
[95,342]. To verify these cells were still in their undifferentiated state, immunofluorescence (IF) 
studies were performed to assess the expression of pluripotency markers, including cell-surface 
stage specific antigens (SSEA-1 & SSEA-4) and keratin sulfate associated Antigen (TRA-1-81) 
(Fig. 22, A-C). Both SSEA-4 and TRA-1-81 are markers of pluripotency in human embryonic 
stem (ES) cells and human carcinoma cell lines, though SSEA-1 is only upregulated in mouse ES 
cells (Fig. 22 C) [350]. IF images for these markers showed that after seven days of culture 
NKX2.1-GFP hiPSCs were still in a pluripotent state since they only were positive for SSEA-4 
and TRA-1-81 (Fig. 22 A, B).  
 
Figure 22: hiPSCs express pluripotency markers 
hiPSCs were cultured for on matrigel coated glass cover slips. At day seven, these cells were then subjected to IF for 
imaging of SSEA-4 (546nm) (A), TRA-1-81 (488nm) (B) and SSEA-1 (488nm) (C). hiPSCs were positive for human 
pluripotency markers SSEA-4 and TRA-1-81, but not for the murine pluripotency marker SSEA-1 (C). 
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3.3.3 Organoids express marker of type-2 alveolar epithelial cells (ATIIs) 
Alveolar organoids were differentiated from the hiPSC surfactant protein-C (SPC) cell line 
developed at the Kotton Lab. The hiPSC SPC cell line expresses a tdTomato reporter allele before 
exon-1 of SPC to verify their differentiation into type-2 alveolar epithelial cells (ATIIs) [208]. 
Upon receiving the sample from the Kotton Lab, alveolar organoids were cultured in 75 µl droplets 
of 3D Matrigel for 8 days (Fig. 23 A). To confirm alveolar organoids were still in their 
differentiated state, 3D cultures were subjected to fluorescence microscopy to verify expression of 
SPC (Fig. 23 B, C). 
 
 
Figure 23: Alveolar organoid culture and characterization 
Alveolar organoids were cultured in 75 µl droplets of 3D Matrigel in CK+DCI media. A graphical representation of 
the culture conditions (A) is followed by microscopic images in grey scale (B) and under the tetramethylrhodamine 
(TRITC) channel (C). This shows alveolar organoids after 8 days of culture were able to maintain their differentiated 
state as ATIIs shown by their expression of surfactant protein-C (SPC, red). 
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3.3.4 Organoids do not release IL-33 in response to Alternaria alternata 
To test the hypothesis that alveolar organoids mainly comprised of ATIIs release IL-33 in 
response to allergens, alveolar organoids were treated with varying concentrations of AA (Fig. 24). 
Lower concentrations of AA (1, 5, 10 µg/ml) were used to stimulate alveolar organoids since the 
amount of cellular material in the 75 µl droplet was significantly less than isolated primary alveolar 
epithelial cells. After stimulation for 6 hours, extracellular media supernatants as well as matrigel 
supernatants and cell lysates were harvested and probed for human IL-33 (Fig. 24 A-C). Using 
ELISA, no detectable levels of IL-33 were found in any of the treatment group samples.  
 
Figure 24: Human IL-33 release from alveolar organoids 
Alveolar organoids were stimulated with 0, 1, 5 and 10 µg/ml of Alternaria in CK+DCI media for 6 hours at D8 of 
their culture. Subsequently, extracellular media supernatants (A), matrigel aggregates (B) and cells lysates (C) were 
harvested and subjected to ELISA for detection of human IL-33. The dashed line at y=46.9 pg/ml indicates the 
detection limit. Statistical significance was determined using a One-way ANOVA, followed by Bonferroni’s Multiple 
Comparisons test, p<0.05 was considered significant.  
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3.4 Discussion 
Allergen induced IL-33 release from lung epithelial cells is a complex process, which may 
involve potentially multiple cell types. Prior studies found no increased levels of murine IL-33 
within the whole lung homogenates of RAGE-/- mice after stimulation with Alternaria alternata 
(AA) [114].Yet, it remains unknown which RAGE expressing lung epithelial cell type releases IL-
33 in response to allergens in a RAGE dependent manner. This led to the hypothesis that type-1 
alveolar epithelial cells (ATIs), which express the highest levels of RAGE in the lung, could be 
the primary cell that releases IL-33 in response to allergens [338,339]. Conversely, treating 
primary lung epithelial cells isolated from murine lung tissue using the ATI specific marker T1-α 
with high concentrations of AA did not induce IL-33 release into the extracellular media (Fig. 14). 
After assessing the purity of these cells using immunoblotting, markers of mesenchymal cells and 
type-2 alveolar epithelial cells (ATIIs) were found (Fig. 13).  
To increase the purity of primary murine ATIs, multiple negative selection antibodies 
targeting endothelial cells and ATIIs were added to the gating strategy using protocols developed 
in the literature (Fig. 15, 18) [346]. After confirming the primary murine lung epithelial cells were 
indeed ATIs, these cells were stimulated with AA. Though no detectable IL-33 were found in the 
media supernatants (Fig. 21). This was true for cells isolated from either WT or RAGE-/- mice. 
The major limitation of these experiments is the lack of the immune system and presence of only 
one lung epithelial cell type. During type-2 airway inflammation, alveolar macrophages and 
dendritic cells sequester allergen antigens and present them to CD4+ T-cells, while barrier 
epithelial cells in the lung (bronchial epithelial cells, or alveolar epithelial cells) exposed to 
allergen antigens produced cytokine alarmins IL-33, TSLP and IL-25 [154]. The release of these 
cytokine alarmins is thought to occur by recognition by pattern recognition receptors, such as 
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RAGE and Toll-like receptors [114,166]. These cytokine alarmins then activate ILC2s and further 
perpetuate the activation of type-2 airway inflammation, dendritic cells and CD4+ T-cells 
[154,167].  
Intriguingly, lung epithelial cells found to express or release IL-33 in models of allergen 
driven type-2 airway inflammation, such as ATIIs and HBECs, have also been found to express 
MHC-II [150,202,341,351]. In this study, antibodies targeted to MHC-II were used to selectively 
isolate ATIIs from murine lung tissue (Fig. 15, 18) [346]. Thus, it is possible ATIIs or HBECs 
may act to further perpetuate type-2 airway inflammation via presentation of allergen antigens to 
the immune system. Indeed, studies have shown ATIIs expressing surfactant protein-C (SPC) in 
mice present influenza antigens to CD4+ T-cells in vivo [352]. While studies have not shown 
MHC-II is required for IL-33 expression or release from lung epithelial cells, MHC-II recognition 
of allergen antigens may be a critical mechanism for lung epithelial cells to communicate to the 
immune system, leading to further release of cytokine alarmins, such as IL-33, from lung epithelial 
cells [353]. In summary, properly investigating how IL-33 is upregulated in the lung epithelium 
requires identification of lung epithelial cell types in vivo that upregulate IL-33 in response to 
allergens in the presence of the immune system. These future experiments will be further 
considered in the following chapter.  
In this study, methods were adapted to model human embryonic developmental cues in 
vitro to produce stable alveolar organoids from human induced pluripotent stem cells (hiPSCs) 
[95,208]. To employ these models, hiPSCs were cultured in an undifferentiated state for expansion 
and future differentiation experiments (Fig. 22). Since ATIIs have been shown to express IL-33 in 
models of type-2 AAI, hiPSC derived alveolar organoids mainly comprised of ATIIs were used to 
investigate their role in IL-33 release in response to the allergen AA [150]. After verifying alveolar 
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organoids were in their differentiated state by assessing expression of surfactant protein-C (SPC), 
alveolar organoids were treated with varying concentrations of AA (Fig. 23). While multiple 
studies have shown ATIIs express IL-33 in the context of type-2 AAI,  IL-33 was not detected in 
the media, cell lysates or matrigel supernatants in response to AA stimulation [150,151] (Fig. 24). 
However, alveolar organoids were cultured in a miniscule 75 µl 3-D matrigel droplet that greatly 
reduces the totally amount of cellular material in the culture compared to a 2-D culture system. 
Thus, it is plausible the limited number of alveolar organoids in each well resulted in low IL-33 
production, which was not detected using a human IL-33 ELISA (Fig. 24). 
Many lung epithelial cell types have been identified to express or harbor IL-33 in models 
of type-2 AAI, including ATIIs, serous (clara) cells, bronchial and basal epithelial cells 
[150,202,340,348]. Even though RAGE is required for IL-33 upregulation in the whole lung and 
ATIs express RAGE more than any other lung epithelial cell, multiple lung epithelial cells may be 
involved in IL-33 release [114]. In one experiment, we showed a population of murine lung 
epithelial cells had both markers of ATIs and ATIIs, RAGE and pro-surfactant protein C (pro-
SPC) (Fig. 13). Even with both populations of alveolar epithelial cells, AA treatment did not induce 
a significant amount IL-33 release in comparison to the control treated cells (Fig. 14). Since 
mesenchymal cells expressing vimentin were also present within this population, it is possible they 
may have inhibited release of IL-33 from other lung epithelial cells in the culture (Fig. 13). This 
study also shows RAGE expression did not affect IL-33 release from lung epithelial cells that only 
expressed markers of ATIs (Fig. 20, 21).  
An assumption of this work is that IL-33 is already present within the cell and is 
subsequently released upon allergen stimulation. However, prior studies found no detectable IL-
33 present in control treated WT or RAGE-/- animal whole lung homogenates [114,202]. This 
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suggest IL-33 does not reside in the nucleus of lung epithelial cells in vivo and is actually 
transcribed upon allergen stimulation. Indeed, other studies detected low levels of IL-33 in lung 
epithelial cells in control treated animals where IL-33 was found to significantly increase in 
animals treated with viruses or allergens [150,151,341]. 
For future studies, murine in vivo experiments would allow specific labeling of lung 
epithelial cells and IL-33 simultaneously to determine which cell types play a role in allergen 
induced IL-33 expression. These experiments could then inform in vitro experiments to test the 
direct role of RAGE in IL-33 release or expression from epithelial cells found to upregulate IL-33 
in vivo. It would also be interesting to see how coculture of lung epithelial cells, such as ATIs, 
ATIIs, basal and bronchial epithelial cells affect IL-33 release. Since we also did not see a 
definitive response from the alveolar organoid cultures, further development or larger cultures of 
hiPSC derived lung epithelial cell organoids would serve as a more useful human model to 
elucidate where IL-33 is released in response to allergens. These future experiments will be further 
explored in the following chapter. 
3.5 Final Conclusions: Chapter 2 & 3 
The studies presented in this work addressed two key questions related to how RAGE plays 
a role in the development of type-2 airway inflammation in cystic fibrosis (CF) and asthma (Fig. 
1, H1 and H2). In patients with CF, type-2 proinflammatory cytokines IL-13 and IL-5 are 
associated with the development of bronchiectasis, P. Aeruginosa infection and are elevated in the 
bronchoalveolar lavage fluid (BALF) when compared to Non-CF controls [37]. IL-13 and IL-5 are 
also found in P. Aeruginosa mucus biofilms that approximately 80% of patients with CF develop 
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[90]. Whereas in asthma patients, IL-13 and IL-5 are two key biomarkers that establish the main 
endotypes of asthma, Th2 “high” and Th2 “low” [149,170]. Consequences of elevated type-2 
airway inflammation ultimately lead to declined lung function measured  by the forced expiratory 
volume in one second (FEV1) in both CF and asthma patients, which is associated with mortality 
in both patient populations [37,177,283].   
In the first study presented in chapter 2, RAGE was found to regulate the direct effects of 
IL-13 on the bronchial epithelium using human bronchial epithelial cells (HBECs). This included 
the expression of the mucin gene MUC5AC, transcriptions factors known to induce mucus 
metaplasia in mice and the production of eotaxin-2, a chemoattractant for eosinophils (Fig. 3, 6, 
7). Mucus production, mucus plugging and eosinophilia are clinical features in asthma and CF 
patients, indicating RAGE inhibition may block these phenomena in patients with elevated levels 
of type-2 proinflammatory cytokines [36,37,290,354]. Indeed, clinical studies looking to block 
type-2 airway inflammation using monoclonal antibodies targeted to IL-5 (mepolizumab and 
reslizumab) and the IL-4Rα/IL-13Rα complex (depilumab) reduce pulmonary exacerbations, 
eosinophilia and the need to use corticosteroids in asthma patients [187–189]. In addition, this 
study showed using WT and RAGE-/- mice that RAGE regulates mucus production in response to 
exotoxin derived from P. Aeruginosa (Fig. 11). Infection with P. Aeruginosa seen in both CF and 
asthma patients and increases the risk of developing a pulmonary exacerbation in both disease 
states [34,36,37,355]. Thus, RAGE inhibition may also reduce mucus production and pulmonary 
exacerbations associated with P. Aeruginosa infection in CF and asthma patients. Though, further 
in vivo studies investigating P. Aeruginosa infection in WT and RAGE-/- animals should be 
conducted. 
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The study presented in chapter 3 sought to identify the RAGE expressing lung epithelial 
cell type responsible for IL-33 release in response to allergen stimulation. This is based on prior 
work showing RAGE is required for IL-33 upregulation in the lung in response to stimulation with 
the allergen Alternaria alternata (AA) [114]. Initially, it was hypothesized type-1 alveolar 
epithelial cells may be the RAGE expressing lung cell type responsible for IL-33 release. However, 
isolation and culture of ATIs from mice show ATIs are not solely responsible for IL-33 release in 
response to stimulation with AA (Fig. 14-21). This was also true when using a human alveolar 
organoid model, which is mainly comprised of type-2 alveolar epithelial cells (ATIIs) where no 
IL-33 was found to be released after stimulation with AA (Fig. 24, 25).  
While this study was unable to uncover the exact cell type(s) responsible for IL-33 release, 
prior work showing RAGE regulates IL-33 upregulation in the lung is a critical finding related to 
the pathogenesis of both asthma and CF. Single nucleotide polymorphisms in IL-33 are associated 
with asthma diagnosis, while IL-33 is found to be upregulated in basal epithelial cells in CF patient 
lung explants [326,356]. The latter finding may also inform future experiments to investigate how 
RAGE regulates IL-33 release in basal epithelial cells in models of CF.  
Interestingly, when CF HBECs are exposed to P. Aeruginosa expression of IL-33 increases 
through regulation by toll-like receptors, which have significant structural similarity to RAGE 
[282,357]. Since P. Aeruginosa infection is seen in both asthma and CF patients, and is associated 
with pulmonary function in both patient populations, RAGE inhibition may deplete IL-33 
production in models of P. Aeruginosa infection. This may lead to novel treatments for patients 
with asthma or CF presenting with a P. Aeruginosa infection [36,355]. 
Depletion of IL-33 through RAGE inhibition has also been shown in vivo to reduce the 
activation of group-2 innate lymphoid cells (ILC2s), which produce IL-13 [114]. Concomitantly, 
 106 
this study and others show RAGE plays a role in the direct effects of IL-13 induction of mucus 
production through activation of STAT6 in the bronchial epithelium (Fig. 10) [112]. This indicates 
RAGE inhibition in asthma and CF patients could target IL-13 induced mucus production and 
eosinophilia in the bronchial epithelium through reduced activation of STAT6, as well as through 
reduction of IL-33 expression in the lung that leads to the production of IL-13 from ILC2s 
[112,114,292]. In summary, RAGE plays a multifaceted role in type-2 airway inflammation seen 
in asthma and CF by regulating the production of IL-33 in the lung, the direct effects of IL-13 on 
the bronchial epithelium, and mucus production in response to exotoxin derived from P. 
Aeruginosa. 
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4.0 Future Directions 
4.1 Rage regulation of mucus production in Cystic Fibrosis 
4.1.1 Role of RAGE in CF  
While RAGE expression, protein abundance and its mutations have been found to be 
associated with CF, prior studies have not addressed how RAGE may modulate lung inflammation 
in models of CF. This study asked how RAGE regulates type-2 airway inflammation using in vitro 
and in vivo models of CF. Prior work found RAGE mRNA and protein levels are elevated in the 
sputum of CF patients, while the anti-inflammatory RAGE isoform sRAGE was decreased in CF 
sputum compared to Non-CF patients [228]. Other studies have found RAGE single nucleotide 
polymorphisms (SNPs) are associated with decreased lung function in CF patients [293]. Since 
prior work implicated RAGE in multiple steps of type-2 airway inflammation, and since CF 
patients have higher levels of type-2 proinflammatory cytokines, increased mucus production and 
eosinophilia, we hypothesized RAGE may regulate type-2 airway inflammation in CF 
[37,112,114,288,307].  
Recombinant human IL-13 (rIL-13) was used to induce mucus production in Non-CF and 
CF primary HBECs. Using the small molecule inhibitor of RAGE (FPS-ZM1), this study found 
RAGE regulates mucin gene expression, mucous hyperplasia, the expression of mucous metaplasia 
transcription factors and the production eotaxin-2 (Fig. 3-7). To understand how RAGE can 
modulate all these processes within CF HBECs, phosphorylation of STAT6 was analyzed using 
immunoblotting. STAT6 is a critical transcription factor required for mucin gene expression, 
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mucous metaplasia and transcription of eotaxin-2 [173,292,303].  Inhibition of RAGE using either 
FPS-ZM1 or dicer substrate siRNA (dsiRNA) targeted to RAGE was able to block phosphorylation 
of STAT6 during rIL-13 stimulation in CF HBECs (Fig. 9, 10). These studies are the first to 
mechanistically link previous associations between RAGE and CF lung function.   
While this study shows RAGE may modulate these processes through activation of STAT6, 
this was only shown at 24 hours post transfection (Fig. 10 A). As well, it is not clear why knock-
down of RAGE expression in Non-CF HBECs during rIL-13 stimulation did not block activation 
of STAT6 (Fig. 10 C, E). In order to address these unanswered question, future in vitro experiments 
will be proposed herein. Alternative experiments will also be proposed to better understand how 
RAGE and its isoforms may play a role in CF type-2 airway inflammation.  
4.1.2 Pseudomonas aeruginosa driven type-2 airway inflammation in CF 
To induce type-2 airway inflammation in vivo, exotoxin derived from P. aeruginosa was 
administered intranasally to WT and RAGE-/- mice. P. aeruginosa is the most common lung 
infection in adult CF patients [358]. Concomitantly, infection with P. aeruginosa is associated 
with decreased lung function and increased mortality in CF patients [90,309]. These infections are 
particularly troublesome since the gram-negative bacteria develop viscous mucus biofilms, which 
aid in the development of antibiotic resistant strains of P. aeruginosa and limit antibiotic 
effectiveness [38]. In order to model this infection in vivo, researchers utilize exotoxin, the most 
potent antigen present on the cell wall of the bacteria [315]. Since studies have found type-2 
proinflammatory cytokines are associated with P. aeruginosa infection in CF patients, we 
hypothesized RAGE may regulate exotoxin induced type-2 airway inflammation in vivo [36,37].  
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The exotoxin treatment schedule based on prior work using this model [88]. After 
intranasal treatment of WT and RAGE-/- C57BL/6 mice with exotoxin (50 µg) for seven days, 
whole lung sections, RNA and the bronchoalveolar lavage fluid (BALF) were harvested. 
Intriguingly, RAGE-/- mice were protected from exotoxin driven type-2 airway inflammation 
using PAS staining of whole lung sections (Fig. 11 M-Q). RT-qPCR analysis of whole lung RNA 
showed increases in Il-13 and Clca1 expression in WT mice treated with exotoxin, though this was 
absent in RAGE-/- mice (Fig. 11 R). Using ELISA analysis of the BALF, we found a similar 
increase in the production of eotaxin-2 in WT mice treated with exotoxin, which was absent in the 
RAGE-/- animals (Fig. 11 S).  
Intriguingly, STAT6-/- mice are also protected from type-2 airway inflammation during 
exotoxin treatment [88]. Pairing these results with our in vitro data indicates RAGE may modulate 
type-2 airway inflammation through phosphorylation of STAT6 (Fig. 9, 10). Importantly, prior 
studies show RAGE-/- have reduced activation of STAT6 over time after stimulation with IL-13. 
While RAGE-/- mice were protected from type-2 airway inflammation using PAS staining, there 
were no significant increases in expression of Il-13, Clca1 or eotaxin-2 production (Fig. 11 R, S). 
This indicates exotoxin treatment for one-week was not sufficient to induce a robust type-2 
immune response in these animals. Conversely, prior studies indicate treatment for one-week with 
exotoxin increases mucus production in the airways, while at 16 hours post treatment mice develop 
small airway constriction and neutrophil influx [315,359]. In the future, it will be pertinent to 
increase exotoxin exposure and to verify if RAGE-/- mice treated with exotoxin have reduced 
activation of STAT6 when compared to WT treated animals. To address these unanswered 
questions, future experiments are proposed herein.  
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4.1.3 Future investigations: Regulation of type-2 airway inflammation in CF 
4.1.3.1 Extended dsiRNA in vitro experiments 
To further explore RAGE regulation of pSTAT6, it would be useful to carry out longer 
term dsiRNA knock-down experiments. Non-CF and CF HBECs could first be transfected with 
the same control or RAGE targeted dsiRNA constructs for six hours. After 20 hours post 
transfection, cells could then be stimulated with rIL-13 for four hours to induce phosphorylation 
of STAT6 (Fig. 25 A). Preliminary data show dsiRNA knock-down is present at 48 hours and CF 
HBECs maintain activation of STAT6 longer than Non-CF HBECs (Fig. 25 B, C). Indeed, Non-
CF HBECs treated with rIL-13 had no pSTAT6 present at 48 hours using western blot analysis 
(Fig. 25 B). This further supports CF HBECs are hyperresponsive to rIL-13 treatment and that 
RAGE regulates this sustained phosphorylation of STAT6. 
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Figure 25: CF HBECs have sustained activation of STAT6 
Undifferentiated primary Non-CF and CF HBECs were first transfected with either a non-targeted dsiRNA (dsiCON, 
100 nM) construct or a pool of three dsiRNA constructs targeted to RAGE expression (dsiRAGE, 100 nM). 
Transfection was carried out using RNAiMax in antibiotic free media for six hours, after which the media was changed 
(A). Cells were then treated with rIL-13 dissolved in saline (10 ng/ml in media) or saline as the vehicle control for 
four hours before RNA or cell lysates were harvested at 48 hours (A). Cell lysates from Non-CF and CF HBECs were 
subjected to gel electrophoresis and immuno-blotting to detect protein abundance of RAGE, STAT6, pSTAT6 and β-
Actin (B, C). N=2.  
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4.1.3.2 Exotoxin in vitro experiments  
It would also be valuable to investigate if RAGE regulates mucus production and mucous 
hyperplasia in response to P. aeruginosa exotoxin. RAGE-/- mice have lower grades of mucus 
production when compared to WT mice treated with exotoxin derived from P. aeruginosa (Fig. 11 
M-Q). This was based on prior studies using exotoxin as a model to induce typ-2 airway 
inflammation in mice. These studies also treated human bronchial epithelial cell lines with 
exotoxin and found exotoxin induced mucous hyperplasia and increased expression of mucin 
genes MUC5B and MUC5AC [89,294]. To see if RAGE may regulate the direct effects of exotoxin 
on the bronchial epithelium, Non-CF and CF HBECs could be treated with FPS-ZM1 and exotoxin 
(12.5 µg/ml) for 48 and 96 hours. In order to test RAGE’s role in this process, experimental groups 
of HBECs would be treated with FPS-ZM1 one hour before exotoxin stimulation. Upon harvesting 
cell lysates for RNA, mucin gene expression and the expression of mucous metaplasia 
transcription factors could be analyzed using RT-qPCR. Since RAGE regulates the direct of IL-
13, and since P. aeruginosa infection increases IL-13 levels, it is plausible that RAGE inhibition 
with FPS-ZM1 may block mucus production and the transcription of mucous metaplasia 
transcription factors in CF HBECs. 
4.1.3.3 sRAGE in vitro experiments  
Another avenue of investigation should study the relationship of CF and the RAGE isoform 
sRAGE. The most common transcript variant of membranous RAGE is soluble RAGE or sRAGE, 
which lacks the transmembrane domain [214,215]. This variant is released extracellularly and acts 
to sequester RAGE ligands and prevent canonical RAGE signaling pathways [220,221]. Thus, 
sRAGE could be used as a way to block RAGE signaling in vitro. Intriguingly, CF patients have 
reduced levels of sRAGE within their sputum [228]. Absence of sRAGE may then perpetuate 
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RAGE singling and subsequent inflammation since it is no longer present to act as a “decoy 
receptor”.  
In order to test if sRAGE could block IL-13 or exotoxin induced mucus production in CF 
HBECs, human sRAGE must first be purified. Human sRAGE could be purified from human lung 
tissue using similar methods described for purification of sRAGE from murine lung tissue [360]. 
Briefly, homogenized human lung tissue would first be mixed with A-Sepharose-4B before 
column compaction. The bulk eluate from this column would then be subjected to heparin-
Sepharose chromatography and fractionization. Fractions containing sRAGE would be analyzed 
using SDS-PAGE gel electrophoresis followed by immunoblotting for human sRAGE. Pooled 
sRAGE fractions would then be dialyzed before anion-exchange chromatography. Final sRAGE 
containing fractions would then be lyophilized to obtain purified sRAGE, which could be 
confirmed using mass spectrometry.  
Using a similar protocol as shown in Fig. 3 A, sRAGE could be administered to Non-CF 
and CF HBECs one hour before stimulation with rIL-13 or exotoxin. After 48 hours, cell lysates 
could be harvested for RNA or total protein. Conversely, at 48 hours HBECs could be given 
sRAGE again one hour before a second stimulation with rIL-13 or exotoxin. Cell lysates could be 
harvested at 96 hours post the first stimulation (Fig. 3 A). RT-qPCR analysis of RNA could then 
be used to see if sRAGE blocks mucin gene expression or the expression of mucous metaplasia 
transcription factors. Total protein could then be subjected to SDS-PAGE gel-electrophoresis and 
immunoblotting to see if sRAGE blocks activation of STAT6. Non-CF and CF HBECs treated 
with sRAGE and rIL-13 or exotoxin could also be fixed, and paraffin embedded for imaging 
analysis. PAS staining or IF staining of RAGE and MUC5AC could then illuminate if sRAGE 
reduces mucous hyperplasia or MUC5AC staining in CF HBECs (Fig. 4, 5). In summary, these 
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studies would begin to uncover if sRAGE would be a suitable treatment for CF patients lacking 
sRAGE. 
4.1.3.4 G82S RAGE expression in vitro 
Another avenue of investigation will be to investigate the RAGE single nucleotide 
polymorphism (rs2070600) associated with FEV1/FVC [98]. This SNP leads to an amino acid 
substitution (G82S) in RAGE’s ligand-binding and enhances the binding affinity of the RAGE 
ligand S100A12, which stimulates mucus production and is associated with asthma [109,250]. 
Human phagocytes heterozygous for the G82S SNP enhances their production of proinflammatory 
cytokines, such as tumor necrosis factor-a (TNF-a) and IL-6, though increased phosphorylation of 
MEK and MAPK downstream of of STAT6 activation [109,292]. Thus, it could be hypothesized 
that G82S RAGE leads to increased phosphorylation of STAT6 in bronchial epithelial cells.  
To express G82S in primary human bronchial epithelial cells (HBECs), clustered 
regulatory interspaced short-palindromic repeats (CRISPR) and the CRISPR associated peptide-9 
(Cas9) endonuclease could be utilized. HBECs would first be transfected a plasmid containing 
Cas9 and a RAGE targeted single- stranded guide RNA (sgRNA) (5μg/5x106 cells) before cells 
undergo differentiation. The plasmid will also express red-fluorescent protein (RFP) with Cas9 to 
identify and isolate Cas9 expressing cells [208]. The experimental group of these cells will 
simultaneously receive a DNA olgio template containing the G82S RAGE SNP (5μg/5x106 cells). 
To integrate G82S RAGE into their genome, Cas9 will generate a double strand break (DSB) 
within the RAGE locus, and the G82S RAGE template will be integrated via homology dependent 
repair (HDR) [361]. Control cells will be transfected with a plasmid containing Cas9 with a non-
targeting sgRNA, and a nonspecific DNA olgio template. The plasmids and oligos will be 
transfected into hiPSCs with a 4D-Nucleofector system via electroporation (Lonza). Transfected 
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HBECs will then be cultured for 48 hours and sorted of RFP+ cells using FACS. After 10 days, 
colonies of sufficient size will be chosen for clonal expansion and genetic screening using PCR 
primers for WT and G82S RAGE. Cells would then be treated with either rIL13 or exotoxin for 
48 and 96 hours to determine if G82S RAGE increases phosphorylation of STAT6, which would 
be determined by SDS-PAGE gel electrophoresis and immunoblotting. 
4.1.3.5 Extended exotoxin in vivo experiments 
After intranasal stimulation of WT and RAGE-/- mice with exotoxin for seven days, Il-13 
expression and eotaxin-2 production in the BALF increased, but these were not significant. In 
order to create a more robust induction of type-2 airway inflammation in these animals, it would 
necessary to extend the exotoxin treatment in WT and RAGE-/- mice. Prior studies treated 
C57BL/6 mice intranasally with exotoxin isolated from P. aeruginosa for 1, 3, 6 and 12 weeks 
[88,89,294]. Schedules ranged from treating every day to treating every three days per week, where 
each treatment was 25 µg of exotoxin. To induce a more robust inflammatory response, WT and 
RAGE-/- should be intranasally administered 50 µg of exotoxin every day for 3-weeks. This will 
provide a greater challenge for RAGE-/- mice, since prior studies show 25 µg of exotoxin was able 
to induce mucous hyperplasia, increases in BALF type-2 proinflammatory cytokines and increases 
in immune cell recruitment to the lung [88,294]. To confirm the new treatment schedule induces 
robust type-2 airway inflammation and that RAGE modulates this response to exotoxin, similar 
analyses should be conducted, including PAS staining of whole lung sections, ELISA of BALF 
eotaxin-2 production and RT-qPCR of whole lung RNA for Il-13 expression and other genes 
upregulated during type-2 airway inflammation. In addition, activation via phosphorylation of 
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STAT6 should be analyzed from whole lung homogenates using SDS-PAGE gel electrophoresis 
followed by immunoblotting for STAT6, pSTAT6, RAGE and β-Actin. 
4.1.3.6 sRAGE in vivo experiments  
To support the above proposed in vitro experiments using sRAGE to block RAGE 
signaling, in vivo experiments using the RAGE isoform should also be considered. As mentioned 
previously, sRAGE acts a “decoy receptor” for RAGE ligands and lacks the transmembrane 
domain [214,360]. Sputum sRAGE is decreased in CF patients and lower levels of sRAGE within 
plasma are associated with decreased lung function in idiopathic fibrosis and COPD patients 
[228,230,236].  In a murine model of chronic sepsis, intraperitoneal treatment with sRAGE (0.5 
and 1 µg) one hour before cecal ligation significantly reduced lung inflammation and overall 
mortality [362]. Other studies have shown intraperitoneal administration of sRAGE in mice does 
not reach the lung, whereas intratracheal administration of sRAGE to mice significantly increases 
organ biodistribution to the lung [256]. Purification of sRAGE from murine lung tissue would be 
conducted based on a previously published protocol for administration to experimental mice [360].  
Based on these studies, two groups of WT C57BL/6 mice could be established, where one 
is given an intratracheal administration of sRAGE (1 µg) and the other a vehicle control. After one 
hour, both groups of mice would receive an intranasal treatment with exotoxin (50 µg). Following 
a 3-week schedule, intratracheal administration with sRAGE would occur every day one-hour 
before intranasal administration with exotoxin. Subsequent harvesting of whole lung sections, 
whole lung RNA and the BALF would then allow for characterization of type-2 airway 
inflammation in these animals. Since reduced plasma sRAGE is associated with reduced lung 
function, it is possible sRAGE, by blocking RAGE signaling, may alleviate exotoxin induced type-
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2 airway inflammation. This would be evidenced by decreased PAS stain positivity, decreased 
mucin gene expression and reduced BALF immune cell accumulation in sRAGE treated animals.  
4.2 IL-33 release during allergic airway inflammation 
4.2.1 Role of IL-33 in type-2 AAI 
IL-33 is a potent initiator of type-2 allergic airway inflammation (AAI). This is based on 
in vivo studies showing the cytokine alarmin induces robust ILC2 proliferation and subsequent 
production of IL-5 and IL-13 when compared to other lung epithelial derived alarmins [141,167]. 
Concomitantly, variants in IL-33 are associated with asthma and IL-33 is elevated COPD versus 
Non-COPD human lung tissue [150,326,348]. Prior studies show RAGE regulates IL-33 
accumulation in the lung during allergen exposure, but do not address which specific lung 
epithelial cell(s) is responsible for its release. IL-33 is upregulated in the whole lung homogenates 
of WT mice exposed to the allergen Alternaria alternata (AA), though is significantly depleted in 
RAGE-/- mice [114]. It is crucial to understand which lung epithelial cell(s) regulate this process 
to enhance our understanding of type-2 AAI and to develop cell specific therapeutics for the 
treatment of asthma.  
The studies presented here began to address the question: Which RAGE expressing lung 
epithelial cell type is responsible for IL-33 release? Work done by Shirasawa et al. showed RAGE 
is a developmental biomarker for type-1 alveolar epithelial cells (ATIs) [338]. Since ATIs are 
adjacent to the vasculature, enabling IL-33 to signal immune cell activation, it was hypothesized 
ATIs could be the RAGE expressing lung epithelial cell responsible for IL-33 release. Though, 
 118 
using primary murine ATIs and stem cell derived alveolar organoids, IL-33 was not detected in 
response to allergen stimulation with AA (Fig. 21, 24). In order to better elucidate this mechanism, 
it is important to understand which lung epithelial cells have been identified to express or release 
IL-33 in response to allergic stimuli. This information can then be used to develop novel 
experiments to uncover where IL-33 is released in the lung and how RAGE may regulate this 
process.   
4.2.2 Lung epithelial cell type expression of IL-33 
While many different lung epithelial cells have been identified to express IL-33 in models 
of airway inflammation, mainly human bronchial epithelial cells (HBECs) have been shown to 
release IL-33 extracellularly in response to allergic stimuli. This is an important distinction since 
upon its release during cell necrosis or allergen stimulation, IL-33 acts as a cytokine alarmin 
activating inflammation and airway remodeling [202,321–323]. Conversely, IL-33 expression 
itself does not fully describe how it regulates type-2 AAI during allergen exposure.  
In vitro studies looking for IL-33 outside the cell have either used cell lines or primary 
HBECs. Primary HBECs exposed to AA were shown to release IL-33 from the nucleus after four 
hours [202]. Another group using the bronchial cell line Beas-2bs showed these cells do not release 
IL-33 after one hour of stimulation with either house dust mite (HDM), AA, Acetosella vulgaris 
(buckwheat) or Betula pendula (silver birch) [201]. Importantly, these studies differ in the methods 
used to detect IL-33 release. While Kouzaki et al. used immunofluorescencent labeling of IL-33 
in fixed HBEC sections, Ramu et al. used ELISA to detect IL-33 in the media supernatants. These 
studies highlight the importance of what allergic stimuli was used, the exposure time, the cell 
type/line and the methods used to detect IL-33 release. 
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In vivo studies had identified even more lung cell types that express IL-33 in models of 
type-2 airway inflammation, including basal cells, serous cells and type-2 alveolar epithelial cells 
(ATIIs) [150,151,341]. Though, only ATIIs have also been implicated in IL-33 release in vivo. 
Mice stimulated with influenza virus for 72 hours had increased IL-33 labeling in ATIIs and had 
elevated IL-33 present within the bronchoalveolar lavage fluid (BALF) [151]. ATIIs have also 
been found to express IL-33 in murine models of COPD and aspirin-exacerbated respiratory 
disease (AERD) [150,341]. Other than ATIIs, serous cells have been identified to express IL-33 
in a murine model of COPD, while only basal cells were found to express IL-33 in human COPD 
lung tissue [150]. This study found no IL-33 expression in basal cells, goblet cells or ciliated 
bronchial cells in the murine COPD model, while no IL-33 expression was found in goblet cells, 
serous cells or ciliated bronchial cells in the human COPD lung tissue [150].  
Since these studies only looked at colocalization of IL-33 with a specific cell type marker 
and did not probe for IL-33 in the BALF, it remains unclear if these cells may release IL-33 after 
exposure to the inflammatory stimulus. In WT mice treated with intranasal AA, production of IL-
33 is significantly increased in the whole lung homogenates. Conversely, global RAGE-/- mice 
treated with AA do not upregulate production of IL-33. Contrary to prior studies showing IL-33 is 
present in the nucleus and is released into the extracellular environment upon allergen stimulation, 
thus not upregulated through gene expression of IL-33, there was no detectible IL-33 within the 
control treated WT or RAGE-/- animal whole lung homogenates [114,202]. This suggest IL-33 
does not reside in lung epithelial cells in vivo and is transcribed upon allergen stimulation. Indeed, 
other studies detected low levels of IL-33 in lung epithelial cells in control treated animals where 
IL-33 was found to significantly increase in animals treated with Sendai virus, influenza or HDM 
[150,151,341]. Considering the differences between these studies looking at IL-33 release or 
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expression in models of airway inflammation, new experimental designs are needed to elucidate 
the true mechanism of IL-33 release during allergen stimulation. 
4.2.3 Future investigations: cell specific IL-33 release during type-2 AAI 
4.2.3.1 Murine in vivo and in vitro experiments   
The most efficient strategy to determine which lung epithelial cell(s) upregulate and release 
IL-33 in the context of allergen stimulation would be to first stimulate IL-33 reporter mice with 
AA. Prior studies investigating localization of IL-33 expression after stimulation with Sendai virus 
used heterozygous IL-33 gene trap mice (IL-33Wt/Gt), where IL-33 expression is maintained in one 
allele and blocked in the second allele due to insertion of a LacZ reporter in intron-1 of the IL-33 
gene locus [363]. This allows heterozygous IL-33 gene trap mice to produce IL-33, inducing IL-
13 accumulation and mucus production, while also labeling IL-33 expressing lung epithelial cell 
types through expression of the β-gal reporter [150].  After intranasal stimulation with Alternaria 
for 10 days every three days, whole lung sections would be obtained from these animals and 
stained for β-gal, DAPI and lung epithelial cell specific markers to determine which lung epithelial 
cell types express IL-33 [114,150]. This experiment would then inform in vitro experiments testing 
the hypothesis that RAGE may regulate IL-33 release in response to allergen stimulation. Several 
in vitro models could be used, including 1) primary murine lung cells 2) primary human lung cells 
or 3) human induced pluripotent stem cells (hiPSCs) differentiated to specific lung cell types. 
For primary murine lung cells, ATIIs and serous cells could be isolated from enzymatically 
digested mouse lung tissue using fluorescence activated cell sorting (FACS) for positive markers 
of ATIIs or serous cells, while also negatively sorting for other cell types, such as endothelial cells 
or leucocytes (see Fig. 15, 18). ATIIs have been shown in mice to express and release IL-33 during 
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stimulation with influenza or Sendai viruses, while serous cells have been shown to express IL-33 
in mice treated with Sendai virus [151,167]. However, the proposed in vivo experiment using AA 
stimulation in IL-33 reporter mice would uncover which lung epithelial cell types upregulate IL-
33 in response to allergen stimulation.  
To test the hypothesis that RAGE may regulate IL-33 release during allergen stimulation, 
cells found to upregulate IL-33 should be isolated from WT and RAGE-/- mice. For example, WT 
and RAGE-/- cultures of ATIIs and serous cells could then be treated with an assortment of 
allergens including house dust mite (HDM), AA, Acetosella vulgaris (buckwheat) or Betula 
pendula (silver birch) for 4 hours. This is based on the in vitro studies showing IL-33 was released 
outside the cell after 4 hours using AA treatment, but was not seen after only one hour of AA 
treatment [201,202]. However, it would applicable to conduct a time course of 2, 4, 6- and 8-hour 
stimulations to determine the time required for IL-33 expression and release from these epithelial 
cells. IL-33 expression and release could then be quantified by RT-qPCR, ELISA or by fixing lung 
epithelial cell cultures for immunofluorescent labeling of IL-33. Coculture of these lung epithelial 
cells could also be treated with allergens to see if multiple cell types are required for IL-33 release. 
This is because multiple lung epithelial cells have been found to upregulate IL-33 in models of 
asthma, chronic obstructive pulmonary disorder and during viral infection [150,151,202]. 
Conversely, IL-33 release from a specific cell type may be dependent on the specific stimuli since 
these studies used different approaches to induce type-2 lung inflammation. 
4.2.3.2 Human in vitro experiments   
Experiments using primary human lung cells or hiPSC derived lung organoids could use 
either ATIIs or HBECs. This is based on studies showing ATIIs in COPD human lung tissue 
express high levels of IL-33, and HBEC cultures stimulated with the allergen AA have been found 
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to release IL-33 after 4 hours [150,202]. Though, cell type selection should be informed by in vivo 
experiments using heterozygous IL-33 gene trap mice. For isolation of ATIIs or HBECs from 
human lung tissues, FACS could be used to select for cells expressing markers for these cell types 
while negatively selecting for other lung cells, endothelial cells or leukocytes. FACS gating 
strategies used in this study were adapted from Nakano et al. and could also be applied to 
enzymatically digested human lung tissue [346]. To test if RAGE regulates IL-33 release from 
these primary human lung cells, the small molecular inhibitor of RAGE, FPS-ZM1, could be 
administered one hour before allergen stimulation to block RAGE signaling. Multiple allergens 
should be used to see if RAGE may play a role during specific allergic stimuli. 
Recent methods have been developed to differentiate hiPSCs into lung epithelial cells of 
the alveolus and the bronchus [95,208]. In the second study, hiPSC derived alveolar organoids 
mainly comprised of ATIIs were exposed to the allergen AA for 6 hours (Fig. 23). Though, ELISA 
analysis showed no IL-33 was present in the media or matrigel supernatants (Fig. 24). Previous 
studies have shown these organoids do not express RAGE, though other studies have shown ATIIs 
can express the pattern recognition receptor [208,364]. Further experiments should verify RAGE 
expression in the hiPSC derived ATIIs using RT-qPCR. If they do express RAGE, then FPS-ZM1 
could be used to determine if RAGE plays a role in IL-33 release from hiPSC derived alveolar 
organoids.  
hiPSC derived bronchial epithelial cell organoids have also been developed [95]. Since 
prior studies have shown primary HBECs can release IL-33, it would be of interest to see if 
bronchial organoids mimic the immunological functions seen in primary HBECs. In order to test 
RAGE’s role in IL-33 release from bronchial organoid cultures, RAGE expression should be 
verified via RT-qPCR. If the HBEC organoid model indeed expresses RAGE, then two groups of 
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organoid cultures could be established, where one receives only the allergic stimuli and the other 
is treated with the RAGE inhibitor FPS-ZM1 before allergen stimulation. A time course of 2, 4, 6- 
and 8- hours should be used to determine the time required for IL-33 expression and release. As 
stated before, IL-33 release could be analyzed in the media and matrigel supernatants from these 
cultures using ELISA. In addition to inhibiting RAGE pharmacologically, it would be beneficial 
to knock-down RAGE expression. This could be done by transfecting siRNA targeted to RAGE 
in these organoid cultures before allergen stimulation and could be compared to cells given a 
scramble or non-targeted siRNA construct before allergen stimulation.  
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Appendix A  
Multiple samples of CF and Non-CF HBECs were used for pharmacological inhibition 
and knock-down of RAGE expression experiments. Mutations and prior disease states of these 
samples are listed below if known.  
Table 1: Non-CF and CF HBEC samples 
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Figure 26: Immunofluorescent images of Non-CF HBECs 
Pre-merge immunofluorescent images of Non-CF HBECs cross-sections during control conditions (A), rIL-13 
stimulation (B) and RAGE inhibition with FPS-ZM1 (C). Primary antibodies used to target RAGE and MUC5AC 
were diluted at 1:100 ratio. Secondary antibodies, goat anti-rabbit IgG at (546 nm-red, RAGE) and goat anti-mouse 
IgG1 (488 nm-green, MUC5AC), were dissolved in PBS at a 1:500 ratio. Nuclei were stained using DAPI. Prior 
disease states of the Non-CF HBECs were interstitial lung disease (ILD) and rheumatoid arthritis (RA). Images were 
taken at 200X magnification. Scale bars = 20 µm. 
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Figure 27: Immunofluorescent images of CF HBECs 
Pre-merge immunofluorescent images of CF HBECs cross-sections during control conditions (A) rIL-13 stimulation 
(B) and RAGE inhibition with FPS-ZM1 (C). Primary antibodies used to target RAGE and MUC5AC were diluted at 
1:100 ratio. Secondary antibodies, goat anti-rabbit IgG at (546 nm-red, RAGE) and goat anti-mouse IgG1 (488 nm-
green, MUC5AC), were dissolved in PBS at a 1:500 ratio. Nuclei were stained using DAPI. CFTR mutations for the 
CF HBECs were of class I (G542X) and II (ΔF508+). Images were taken at 200X magnification. Scale bars = 20 µm. 
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Figure 28: Total STAT6 is not significantly depleted at 24 hours 
Fold change expression of STAT6 for Non-CF (white, A) and CF HBECs (black, B) were calculated using Image 
Studio densitometry software and means represent three replicates for each culture condition. Statistical significance 
was determined using an Unpaired Student’s T-test, p<0.05 was considered significant, N=2.  
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Figure 29: Power analyses on RAGE expression and RAGE inhibition experiments 
Power analyses were conducted in Minitab (Trialware, State College, PA) to determine if there was adequate statistical 
power for the RAGE expression analysis (Fig. 2, 29 A), and to determine the sample size required for future RAGE 
inhibition experiments looking at phosphorylation of STAT6 (Fig. 9, 29 B). Statistical power was determined in 29 A 
(1-β=0.967), whereas in 29 B sample size per treatment group or n was solved for based on a power set to 0.85 (n=3). 
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Figure 30: Brown-Forsythe test for MUC5AC expression at 48 and 96 hours 
The Brown-Forsythe test was conducted for MUC5AC expression from Fig. 3 A and D to test for equal variance. The 
Brown-Forsythe was conducted using GraphPad PRISM 8 software where a P<0.05 is considered significant. If 
P<0.05, then the variance is statistically different for a gene’s expression. If P is >0.05 variance is not statistically 
different. Since ANOVA is robust to changes in variance if the sample size is equal, a 3-WAY ANOVA was used to 
analyze the three effects on gene expression followed by Bonferroni’s multiple comparisons test that does not require 
equal variance: CF, IL13 and the RAGE inhibitor. 
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Figure 31: Brown-Forsythe test for CLCA1, SPDEF and FOXA3 expression at 48 hours 
The Brown-Forsythe test was conducted for CLCA1, SPDEF and FOXA3 expression from Fig. 6 A to test for equal 
variance. The Brown-Forsythe was conducted using GraphPad PRISM 8 software where a P<0.05 is considered 
significant. If P<0.05, then the variance is statistically different for a gene’s expression. If P is >0.05 variance is not 
statistically different. Since ANOVA is robust to changes in variance if the sample size is equal, a 3-WAY ANOVA 
was used to analyze the three effects on gene expression followed by Bonferroni’s multiple comparisons test that does 
not require equal variance: CF, IL13 and the RAGE inhibitor. 
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Figure 32: Brown-Forsythe test for CLCA1, SPDEF and FOXA3 expression at 96 hours 
The Brown-Forsythe test was conducted for CLCA1, SPDEF and FOXA3 expression from Fig. 6 C to test for equal 
variance. The Brown-Forsythe was conducted using GraphPad PRISM 8 software where a P<0.05 is considered 
significant. If P<0.05, then the variance is statistically different for a gene’s expression. If P is >0.05 variance is not 
statistically different. Since ANOVA is robust to changes in variance if the sample size is equal, a 3-WAY ANOVA 
was used to analyze the three effects on gene expression followed by Bonferroni’s multiple comparisons test that does 
not require equal variance: CF, IL13 and the RAGE inhibitor. 
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